TW200940081A - A plant composition - Google Patents

A plant composition Download PDF

Info

Publication number
TW200940081A
TW200940081A TW098105514A TW98105514A TW200940081A TW 200940081 A TW200940081 A TW 200940081A TW 098105514 A TW098105514 A TW 098105514A TW 98105514 A TW98105514 A TW 98105514A TW 200940081 A TW200940081 A TW 200940081A
Authority
TW
Taiwan
Prior art keywords
acid
oil palm
extract
composition
solution
Prior art date
Application number
TW098105514A
Other languages
Chinese (zh)
Inventor
Nyie Lin Phang
Khalid Mohd Fairuz Yasmin B Abdul
Chai Kuan Lim
Siti Asmah Bt Hambali
Sharharfiza Bt Shariff
Sangeetha D O Thuraisingam
Original Assignee
Nova Lab Sdn Bhd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nova Lab Sdn Bhd filed Critical Nova Lab Sdn Bhd
Publication of TW200940081A publication Critical patent/TW200940081A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

This invention relates to novel plant extracts that have therapeutic activities. These herbal compositions may be used for reducing oxidative stress in mammals and poultry.

Description

200940081 六、發明說明： 【發明所屬之技術領域】 本發明關於一種對人類或其他演化上較低等之動物皆 具有降低和預防體内氧化壓力之治療功效的油棕葉萃取 物。本發明關於之萃取物尤指其内含部分富含兒茶素沒食 子酸(catechin gallate)、阿魏酸(ferulic acid)以及紛酸(phenolic acid)如;又食子酸(gaiiic acid)和原兒茶酸0r〇t〇catechuic acid) 而產生上述治療功效者。 〇 【先前技術】 油棕(Elaeis)包含原生地為西非之非洲油棕出⑹匕 guineensis)和原生地為中南美洲之美洲油棕〇leifera) 等兩種棕櫚（Arecaceae)樹種。所述非洲油棕（Elaeis gumeensis)因其富含油脂之果實而也廣泛種植於馬來西亞 和印尼。成熟的油棕屬單幹型(single-stemmed)樹種，樹幹 全長可達20公尺。油棕葉屬羽狀葉，葉長可達3至5公尺。 一棵年輕的油棕每年可長出約30片羽狀葉。油棕的花係叢 聚生長’每一朵花含有三個萼片和三個花瓣。 油棕的果實呈淡紅色且成串生長，每一串重達至 公斤。該果實具有富含油脂且肥厚的外表層稱為果皮層 (pericarp)以及含單一種子的棕仁(kemel)。果皮層和棕仁中 皆能萃取出油脂。 種。自 維生素 油掠主要因其可用以生產食用油之果實而被裁 油棕果實萃取之棕櫚油也含有葉紅素(car〇tenes)、 200940081 E(tocopherols)、生育三烯醇(tocotrienols)。已有一些研究指 出油掠葉％取衍生物具有益功效。Abeywardena M，et al (Asia Pac· J. Clin. Nutr.，11: S467 - S472)發表 了關於一富含 多酚的油棕葉(非洲油棕)萃取物。所述萃取物可經由血管内 皮層細胞參與之機制促進血管舒張。但並未提及含有兒茶 素沒食子酸(catechin gallate)、阿魏酸(ferulic acid)、沒食子 酸(gallic acid)和原兒茶酸(pr〇t〇catechuic acid)等成份。也未 提及該萃取物作為抗氧化壓力劑的用途。 O Suhaila Mohamed, et al (WHAT Medicine IH Proceedings, 2007, PP 145-148)揭露富含多酚之油棕葉(非洲油棕)具有抗 高膽固醇血症（hypercholesterolemic)和抗高血壓 (hypertensive)之功效。但並未提及並研究含有兒茶素沒食子 酸(catechin gallate)、阿魏酸(ferulic acid)、沒食子酸(gallic acid) 和原兒茶酸(protocatechuieacid)等成份。也未提及該萃取物 作為抗氧化壓力劑的用途。 ^ Nagendran Balasundram, et al (Asia Pac. J. Clin. Nutr. 2005; 4 (4):319-324)揭露一自油棕果實純化之富含酚醛的部 分。該純化部分表現出生物活性之特性，尤其是抗氧化壓 力的功效。然而’關於所述純化部分之化學成份組成，並 沒有研究與記載。也沒有提及油棕葉萃取物作為抗氧化壓 力劑之用途。200940081 VI. Description of the Invention: [Technical Field of the Invention] The present invention relates to an oil palm leaf extract which has therapeutic effects on reducing or preventing oxidative stress in the body in humans or other animals which are relatively lower in evolution. The extract of the present invention especially includes a part thereof rich in catechin gallate, ferulic acid, and phenolic acid such as gaiiic acid. And the original catechin 0r〇t〇catechuic acid) to produce the above therapeutic effects. 〇 [Prior Art] Oil palm (Elaeis) contains two palm (Arecaceae) species, such as the African oil palm (6) gu guineensis native to West Africa and the native oil palm locust leifera native to Central and South America. The African oil palm (Elaeis gumeensis) is also widely grown in Malaysia and Indonesia for its oil-rich fruits. The mature oil palm is a single-stemmed tree with a trunk length of up to 20 meters. Oil palm leaf is a pinnate leaf with a leaf length of 3 to 5 meters. A young oil palm can grow about 30 pinnate leaves per year. Oil palm flower clusters grow together. Each flower contains three bracts and three petals. The oil palm fruit is light red and grows in bunches, each weighing up to kilograms. The fruit has a fat-rich and hypertrophic outer layer called pericarp and a single seeded kemel. Oil can be extracted from both the peel layer and the palm kernel. Kind. The palm oil extracted from the oil palm fruit is also mainly contained in the oil palm fruit extract, which also contains caroten (car〇tenes), 200940081 E (tocopherols), tocotrienols (tocotrienols). There have been some studies that have shown that the extract of oil plucked leaves has a beneficial effect. Abeywardena M, et al (Asia Pac. J. Clin. Nutr., 11: S467 - S472) published an oil palm leaf (African oil palm) extract rich in polyphenols. The extract promotes vasodilation via a mechanism by which vascular endothelial cells participate. However, there are no mentions of ingredients such as catechin gallate, ferulic acid, gallic acid, and pr〇t〇catechuic acid. There is also no mention of the use of the extract as an antioxidant pressure agent. O Suhaila Mohamed, et al (WHAT Medicine IH Proceedings, 2007, PP 145-148) discloses that polyphenol-rich oil palm leaves (African oil palm) are resistant to hypercholesterolemic and hypertensive efficacy. However, there are no mentions and studies on catechin gallate, ferulic acid, gallic acid and protocatechuieacid. There is also no mention of the use of the extract as an antioxidant pressure agent. ^ Nagendran Balasundram, et al (Asia Pac. J. Clin. Nutr. 2005; 4 (4): 319-324) discloses a phenolic-rich fraction purified from oil palm fruit. This purified fraction exhibits the properties of biological activity, especially the antioxidant pressure. However, there is no research and description regarding the chemical composition of the purified fraction. There is also no mention of the use of oil palm leaf extract as an antioxidant pressure agent.

Tan Y. A., et al (The Royal Society of Chemistry 2001; 548-551)揭露自油掠果實之中果皮層和核仁所萃煉之栋摘 油富含紛搭化合物。所述紛酸化合物包含沒食子酸(gallic)、 200940081 綠原酸(chlorogenic)、原兒茶酸(protocatechuic)、香豆酸 (coumaric)、阿魏酸(ferullic)、咖啡酸(caffeic)以及兒茶素 (catechins)、檸檬黃素(hesperidine)、柚皮元(narirutin)、對羥 基苯甲酸甲酯(4-hydroxybenzoate)。然而，關於油棕葉萃取 物之化學組成並未被研究與揭露。油棕葉萃取物作為抗氧 化壓力劑之用途也沒有被提及。Tan Y. A., et al (The Royal Society of Chemistry 2001; 548-551) reveals that the oil extracted from the peel layer and the nucleolus of the oil-swept fruit is rich in compound compounds. The acid compound includes gallic, 200940081 chlorogenic, protocatechuic, coumaric, ferullic, caffeic, and Catechins, hesperidine, narirutin, 4-hydroxybenzoate. However, the chemical composition of the oil palm leaf extract has not been studied and disclosed. The use of oil palm leaf extract as an antioxidant pressure suppressor has also not been mentioned.

Run-Cang Sun, et al (J. Agric. Food Chem., 49(11), 5122_5129, 2001)揭露一種定量油棕葉纖維中所含經基肉 〇 桂酸（hydroxycinnamic acids)的新方法。然而，並未提及含 有兒茶素沒食子酸(catechin gallate)。油棕葉萃取物作為抗氧 化壓力劑之用途也沒有被提及並研究。Run-Cang Sun, et al (J. Agric. Food Chem., 49(11), 5122_5129, 2001) discloses a new method for quantifying hydroxycinnamic acids contained in oil palm leaf fibers. However, there is no mention of catechin gallate. The use of oil palm leaf extract as an antioxidant pressure suppressor has not been mentioned and studied.

Yew-Ai tan, et al (European Journal of Lipid Science andYew-Ai tan, et al (European Journal of Lipid Science and

Technology，Volume 109, Issue 4, pages 380-393,2007)揭露油 棕果實於提煉和製造掠櫚油時所產生的副產物含有固醇 (sterols)、維生素 E(vitaminE)、類胡蘿蔔素(carotenoids)、磷 ❹ 脂質(PhosPh〇lipids)、鯊烯(squalene)和酚醛(phenolics)等植物 素(phytochemicals)。然而，關於油棕葉萃取物之化學組成並 未被研究與揭露。油標葉萃取物作為抗氧化壓力劑之用途 也沒有被提及並研究。Technology, Volume 109, Issue 4, pages 380-393, 2007) Exposing the by-products produced by oil palm fruit in the refining and production of palm oil, containing sterols, vitamin E, carotenoids ), phytochemicals such as PhosPh〇lipids, squalene, and phenolics. However, the chemical composition of the oil palm leaf extract has not been studied and disclosed. The use of oil-labeled leaf extracts as antioxidant pressure agents has not been mentioned and studied.

Kinnoudo Celestin (WO2009129136)揭露非洲油棕(油棕) 葉萃取物展現抗癔疾的特性。但所述油棕葉萃取物之化學 成份組成並未被研究。且並未提及並研究含有兒茶素沒食 子酸(catechin gallate)、阿魏酸(ferulic acid)、沒食子酸(gallic acid)和原兒茶酸(protocatechuic acid)等成份。也未提及並研 200940081 究該萃取物作為抗氧傾力義用途。 氧化壓力 ▲近十幾年來’因游離態和結合態之活性自由基所具有 成為具破雜分子之躲’其於人類健康與疾 病發生之重要性，已獲得顯著增加之重視。許多常見的威 類生今之疾病如動脈粥狀硬化症(ather〇scier〇sis)、癌症 廣根本之損害制料自自基參與之 病理反應。 0 自由基，或游離態自由基的基本特徵為於外圍電子執 域具有-個衫縣成龍子之分子。許多具有結合態自 由基之刀子種類通稱為活性氧化物(reactive spedes， R0S)如-氧似城其他含魏原子之化合物。賴高度不 敎的分子傾向練速地與_的分子發生反應，以提 供、搶奪或甚至於分享其外圍電子軌域之電子。上述反應 不僅造成該鄰近分子之改變，有時是顯著並有助益的，也 ◎ 可能破壞該分子，或即使所述游離態自由基之未成對電子 可移轉至該鄰近分子，卻會產生下—個不欲見的活性氧化 物，且進而有益或有害地與下一個目標鄰近分子產生反 應。事實上，眾多具有高活性的活性氧化物就是藉由上述 產生它們的分子連鎖反應，有效地使它們產生影響的程度 放大了數倍。 所有存活的好氧型生物係藉著利用氧氣以代謝產出能 量。然而，許多訊息指出，好氧型生物利用氧氣代謝的優 點同時也伴隨著於氧化過程中遭受損害的風險。多種參與 6 200940081 於氧化過程中的活化氧代謝物，同時會攻擊多種生物體内 分子。幾乎所有的化學化合物皆容易受到此類活性氧化合 物的氧化損害。如核酸、蛋白質和游離態的胺基酸、脂質 和碳氫化合物皆會受到氧的侵害。人體具有精細並廣泛運 用且顯然相當重要的系統，來平衡體内的氧化和抗氧化作 用(參考 H. Sies, Oxidative Stress, pages. 2-4 1985)。然而，體 内原生之抗氧化能力往往不足以抵銷不斷增生的活化氧化 物，在這一種情況之下，所謂的「氧化壓力」就會產生。 〇 上述離開平衡而偏向氧化作用之過程，可能包含兩個 原因： 1. 活化氧代謝物的產生量超過抗氧化系統所能負荷的 量；以及， 2. 抗氧化系統本身的能力不足。 上述情況產生的結果統稱為「氧化壓力」。目前已知， 上述偏離平衡的情況可能是由許多不同疾病所引發的，尤 0 指發炎性疾病如肝炎(hepatitis)、中樞神經系統之病變如癲 癇Opilepsy)或帕金森氏症(Parkinson’s disease)、肺臟病變如 氣喘(asthma)、乾癬(psoriasis)、抗癌藥物的副作用、化學劑 如除草劑(paraquat)和輻射造成的副作用以及冠狀循環疾病 如心肌肥厚症(cardiac infaraction)。 雖不願被任何理論所侷限，氧化壓力仍被視為參與人 類或其他動物之疾病與受傷狀態中的一個因子，而經過許 多的研究佐證，即使氧化壓力並不是造成該疾病的原因， 也都對造成該疾病的過程有負向的影響，對該已病變之器 200940081 官的細胞造成更進一步的傷害。 現行可信的科學證據指出，人類和其他動物的許多生 理異常和疾病都與氧化壓力有關。包含： 籲老化(aging):比正常個體老化速度快的加速老化情 形。 •心血管疾病(heart and cardiovascular disease):動脈粥 狀硬化症(atherosclerosis)和阿黴素(adriamycin)造成 的心臟毒性(cardiotoxicily) 〇 ❹ •腎臟(kidney):腎症自體免疫症候群(aut〇immmie nephritic syndromes)和重金屬引發之腎毒性(heavy metal nephrotoxicity) ° •太陽輕射(solar radiation):皮膚敏紋(skin wrinkling) 和色素斑病變(pigmentation)。 鲁眼睛(eye):白内障(cataractogenesis)、退化性視網膜 病變(degenerative retinal damage)、老化性黃斑部病 變(macular degeneration)。 *肺臟(lung):肺癌(抽終引發）、肺氣腫(emphysema)、 氧化劑污染物(oxidant pollutants)如臭氧和二氧化 氣、支氣管發育不良(bronchopulmonary dysphasia)、 石棉引發之癌化(asbestos carcinogenicity)。 •神經系統失序(nervous system disorders):帕金森氏症 (Parkinson’s disease)、神經元蠟樣脂褐質儲積症 (neuronal ceroid lipofuscinoses) ' 阿茲海默症 (Alzheimer’s disease)、肌肉萎縮症（muscular 8 200940081 dystrophy)、多發性硬化症(multiple sclerosis) 〇 _鐵質過度負擔(ironoverload):鐵質沉積症(idiopathic hemochromatosis)、飲食過量(dietary overload)、地中 海型貧血(thalassemia) 〇 春發炎症與免疫損害(inflammatory-immune injury):腎 絲球腎炎(glomerulonephritis)、自體免疫疾病 (autoimmune disease)、類風濕性關節炎(rheumatoid arthritis) 0 ❹ •肝臟(liver) ·酒精引發之肝臟傷害(liver injuries induced by alcohol)、鹵代烴和鎮熱解痛藥物 (paracetamol) 〇 抗氧化劑可提供保護，因其可以在活性氧化物及游離 自由基造成生物體内分子損害前，先一步將活性氧化物及 游離自由基清除，也可以避免氧化造成之損害繼續傳播下 去’如中斷脂質過氧化的自由基連鎖反應。自由基在體内 〇 產生之反應及體内之負荷程度最後所造成的病理狀態，即 所稱之氧化壓力。 在過去’抗氧化劑(自由基清除劑)於上述疾病中消除氧 化壓力之功效已被研究，並且一種具消除自由基功效之消 炎藥劑也已經被開發出來。因此，具有抗氧化能力之物質 於降低氧化壓力之效用是顯而易見的。 維生素如維生素c和社素E特在於日常飲食中並 以營養補充品的肖色鋪取，抑助身雖低氧化壓力的 影響。而於對抗自纟基和活性氧化物上更有效力的是體内 200940081 本身之防齡統所產生之稱為抗氧化_化合物。所述抗 氧化劑可舰供-個電子給自由基和潍氧化物，或阻礙 自由基和活性氧化物的正常構型來終結於活性氧化物上之 游離態和結合態自由基的散佈。 體内的抗氧化防禦系統包含三個重要的天然抗氧化 劑：超氧化歧化酶(superoxide dismutase，SOD)、過氧化氫酶 (catalase，CAT)和麩胺基硫過氧化酶(glutathiQne peiOxid^ GPX)。研究加’當上述抗氧化#1參與之反應於代謝上是 相連續的，上述抗氧化劑可以協合執行工作，從最初的超 氧化歧化酶到接續的過氧化氫酶和麩胺基硫過氧化酶。 體内抗氧化防禦系統若缺乏上述超氧化歧化酶、過氧 化氫酶和楚胺基硫過氧化酶，將使抗氧化防紫系統容易收 到氧化壓力的攻擊’並且抗氧化防素系統產出超氧化歧化 酶、過氧化氫酶和麵胺基硫過氧化酶的能力與老化息息相 關且又到發炎反應、微生物或病毒感染、癌症惡化和神 〇 經系統失序，以及其他造成氧化壓力、受氧化壓力引發、 受氧北壓力加強之病理狀態所促發。 近期以來，有三大主要理由5丨發了尋找天然抗氧化劑 的興趣(Dastmalchi，Dornian，Kosar，& Hiltunen，2007): 1.為數眾多的臨床與流行病學的研究指出，水果與蔬 菜的攝取與降低癌症、心血管疾病和糖尿病等慢性 疾病的風險息息相關； 2·長期以食物或飲品的方式攝取合成抗氧化劑所伴隨 著的安全性顧慮；以及， 200940081 3·大眾普遍認知食用天然和日常飲食中的抗氡化劑較 食用合成的類似物來得安全。這樣的認知增加了使 用藥用植物以獲得天然抗氧化劑的傾向。 來自油棕葉萃取物之化學化合物的抗氧化及抗氧化壓 力的活性尚未被了解。 本發明欲提供一種用以降低哺乳類和鳥類體内氧化壓 力之新穎油棕葉萃取物。所述萃取物富含兒茶素沒食子酸 (catechin gallate)、阿魏酸(ferulic acid)以及酴酸(phenolic acid) © 如沒食子酸(gallic acid)和原兒茶酸(protocatechuic acid)而具 有抗氧化壓力之活性，並且，油棕葉萃取物中綜合兒茶素 沒食子酸(catechin gallate)、阿魏酸(ferulic acid)以及酚酸 (phenolic acid)如沒食子酸(gamc acid)和原兒茶酸 (protocatechuic acid)所具有之功效尚未被提出。 總結來說’來自油標葉卒取物中富含多紛類的部份已 被揭露，所述富含多酚類的部份並用以做為抗高膽固醇血 症和抗高血壓的藥劑，但來自油棕葉萃取物中具有兒茶素 沒食子酸(catechin gallate)、阿魏酸(feruiic aeid)以及盼酸 (phenolic acid)如沒食子酸(gallic acid)和原兒茶酸 (protocatechuic acid)的部份卻尚未被研究並揭露，所述部份 用以作為抗氧化壓力藥劑的功效也尚未被研究並揭露。 【發明内容】 爱疋，本發明之主要目的為提供一種來自油棕葉且對 哺乳類和鳥類具有治療活性的組合物。 200940081 本發明之次一目的為提供一種含有兒茶素沒食子酸 (catechkl gallate)、阿魏酸(femlic add)以及酚酸(phenolic add) 如;又食子酸(gallic acid)和原兒茶酸(pr〇t〇catechuic acid)的組 合物0 本發明之又一目的為提供一種製備油棕葉萃取物的方 法。 本發明之再一目的為提供一種包含新穎萃取物以及至 少一醫藥可接受的載體之醫藥組合物。 本發明之更一目的為提供一種包含新穎萃取物、穩定 劑(stabilizers)、載體(carriers)、賦形劑(excipients)、稀釋劑 (extenders)和其他合適物質之醫藥組合物。 本發明之進一目的為提供一種包含相互混合作用之新 穎萃取物與醫藥可接受的載體且用以降低並避免哺乳類和 鳥類體内氧化壓力之組合物。 為達上述目的’本發明提供一種含有油棕葉萃取物之 組合物’其特徵在於，所述萃取物包含兒茶素沒食子酸 (catechin gallate)、阿魏酸(ferulic acid)以及紛酸(phenolic acid) 如;又食子酸(gallic acid)和原兒茶酸(protocatechuic acid);並 提供一種自油棕葉生產該包含兒茶素沒食子酸(catechin gallate)、阿魏酸(ferulic acid)以及酚酸(phenolic acid)如沒食 子酸(gallic acid)和原兒茶酸(pr〇t〇catechuic acid)之萃取物的 方法，包含以下步驟： (a)將乾燥或新鮮的油掠葉混合以水、酒精、甲醇、丙 嗣、乙酸乙醋、氣仿、異丙醇’或上述溶劑之混合 12 200940081 劑’或其他極性溶劑’再以攝氏25度至95度之溫 度加熱0·5小時至96小時，以萃取油棕葉中的植物 液； (b) 過濾上述步驟a中萃取得到的植物液； (c) 將上述步驟b中過濾過的植物液與可選擇性吸附成 份之吸附層析介質接觸，以保留植物液中的兒茶素 沒食子酸(catechin gallate)、阿魏酸(ferulic acid)以及 紛酸(phenolic acid)如沒食子酸(gaiiic acid)和原兒茶 © acid);所述吸附介質可為管柱吸附 介質’或其他吸附介質； ⑼使用水、酒精、甲醇、丙酮、乙酸乙酯、氯仿、異 丙醇，或上述溶劑之混合劑，或其他極性溶劑將上 述步驟c中吸附之部份植物液自吸附層析介質中溶 離出來，以及， (e)使用傭式乾聽、真空烘箱、普通烘箱、微波洪 〇 箱或冷凍乾燥器任一種乾燥裝置將上述步驟d所得 之植物液乾燥。 本發明之進-目的為仙上述組成物崎低和避免哺 乳類和鳥舰_氧化壓力，包含提供需要練之個體一 含有效劑量之組合物。 【實施方式】 本發明關於—種含有油棕葉萃取物之組合物，其特徵 在於’所述萃取物包含兒茶素沒食子酸(catechin ga_、阿 13 魏酸(fernlic acid)以及紛酸(phenolic acid)如沒食子酸(gallic acid)和原兒茶酸(protocatechuic acid) 〇 上述油掠葉選自非洲油棕(Elaeis guineensis)和美洲油 棕(Elaeisoleifera)任一種油掠屬植物。 本發明之新穎組合物含有重量百分濃度0.1%至95%的 兒茶素沒食子酸(catechin gallate)、重量百分濃度〇.1〇/〇至 95%的阿魏酸(fernlic acid)以及重量百分濃度0.1%至95%的 酚酸(phenolic acid)如沒食子酸(gallic acid)和原兒茶酸 (protocatechuic acid) ° 於本發明之一較佳實施例’上述組合物含有重量百分 濃度0.5%至10%的兒茶素沒食子酸(catechin gallate)、重量 百分濃度1%至5%的阿魏酸(ferulic acid)以及重量百分濃度 5%至30%的酚酸(phenolic acid)如沒食子酸(gaiiic acid)和原 兒茶酸(protocatechuic acid) 〇 於本發明之一理想實施例，上述組合物含有重量百分 濃度0.5°/。的兒茶素沒食子酸(catechin gallate)、重量百分濃 度1%的阿魏酸(fernlic acid)以及重量百分濃度20%的酚酸 (phenolic acid)如沒食子酸(gallic acid)和原兒茶酸 (protocatechuic acid) ° 本發明也關於一用以製備油棕葉萃取物之方法，包含 以下步驟： 將乾燥或新鮮的油棕葉混合以水、酒精、甲醇、丙 酮、乙酸乙酯、氣仿、異丙醇’或上述溶劑之混合 劑’或其他極性溶劑，再以攝氏25度至95度之溫 200940081 度加熱0.5小時至96小時，以萃取油棕葉中的植物 液； (b) 過濾上述步驟a中萃取得到的植物液； (c) 將上述步驟b中過濾過的植物液與可選擇性吸附成 份之吸附層析介質接觸，以保留植物液中的兒茶素 沒食子酸(catechin gallate)、阿魏酸(fernlic acid)以及 盼酸(phenolic acid)如沒食子酸(gamc acid)和原兒茶 酸(protocatechuic acid);所述吸附介質可為管柱吸附 ® 介質，或其他吸附介質； (d) 於攝氏10度至80度’壓力0.1巴至1〇巴之間，使 用水、酒精、甲醇、丙酮、乙酸乙酯、氣仿、異丙 醇，或上述溶劑之混合劑，或其他極性溶劑將上述 步驟c中吸附之部份植物液自吸附層析介質中溶離 出來，以獲得一富含兒茶素沒食子酸(catechin gallate)、阿魏酸(fcrulic acid)以及酚酸恤⑽此add) 〇 如;又食子酸(gallic acid)和原兒茶酸(protocatechuic acid)之萃取物；以及 (e) 以喷霧式乾燥斋、真空供箱、普通供箱、微波烘箱、 冷凍乾燥器或任一種乾燥裝置將上述步驟d所得之 植物液乾燥。 於本發明之-較佳實施例中，於油標葉與溶劑相混合 之萃取裝置中，一伤的乾燥油棕葉，搭配5至份的溶劑 以萃取；於一理想實施例中，搭配10至30份的溶劑以萃 取。於一較佳實施例中’混合時間為丨小時至96小時；於 15 200940081 一理想實施例中’混合時間為8小時至24小時。於一較佳 實施例中，該溶劑之溫度維持於攝氏25度至95度；於一 理想實施例中’該溶劑之溫度維持於攝氏50度至6〇度。 於本發明之一較佳實施例中’用以萃取之溶劑係選自 水、酒精、甲醇、丙酮、乙酸乙酯、氯仿、異丙醇或上述 溶劑之混合劑；於一理想實施例中，係選自水、酒精或酒 ***溶液；於另一理想實施例中，係選用含重量百分濃度 30%的水和重量百分濃度70%的酒精之酒***溶液。 〇 於本發明之一較佳實施例中’該吸附層析介質包含苯 乙婦-二乙稀苯共聚物樹脂(styrene-divinylbezene eopolymei: resin)、苯驗-甲搭樹脂(phenol-formakiehyde resin)、丙婦酸 樹脂(acrylic resin)、曱基丙烯酸酯樹脂(methacryiateresir^和 聚醯胺樹脂(polyamide resin)。上述樹脂之例子為：美國費 城 Rohm&Haas 公司之型號為 Amberlite XAD-1、Amberlite XAD-2、Amberlite XAD-4、Amberlite XAD-7、Amberlite XAD-8、Amberlite XAD-11、Amberlite XAD-12、AmberliteKinnoudo Celestin (WO2009129136) reveals that African oil palm (oil palm) leaf extract exhibits anti-dysentery properties. However, the chemical composition of the oil palm leaf extract has not been studied. It does not mention and study ingredients such as catechin gallate, ferulic acid, gallic acid, and protocatechuic acid. Nor did it mention and research 200940081. The extract was used as an anti-oxidant. Oxidative pressure ▲In the past decade or so, the importance of active free radicals due to free and bound states has become a significant concern for human health and disease. Many common diseases such as atherosclerosis (ather 〇 〇 〇 、 、 、 、 、 、 、 、 、 、 、 、 、 、 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。. 0 The basic feature of free radicals, or free radicals, is that they have a molecule in the peripheral electron domain. Many types of knives with bound free radicals are commonly referred to as reactive spedes (ROS) such as oxygen-like other compounds containing Wei atoms. Highly unmotivated molecules tend to react rapidly with molecules of _ to provide, snatch, or even share electrons in their peripheral electronic orbits. The above reaction not only causes a change in the adjacent molecule, but is sometimes significant and helpful, and ◎ may destroy the molecule, or even if the unpaired electron of the free radical can be transferred to the adjacent molecule, An undesired active oxide, and in turn beneficially or detrimentally reacts with the next target neighboring molecule. In fact, many of the highly active active oxides are multiplied several times by the molecular chain reaction that produces them above, effectively affecting them. All living aerobic organisms metabolize energy by using oxygen. However, many sources indicate that the advantages of aerobic organisms in utilizing oxygen metabolism are also accompanied by the risk of damage during oxidation. Multiple Participation 6 200940081 Activated oxygen metabolites in the oxidation process, while attacking a variety of biological molecules. Almost all chemical compounds are susceptible to oxidative damage by such active oxides. Nucleic acids, proteins, and free amino acids, lipids, and hydrocarbons are all exposed to oxygen. The human body has a sophisticated and widely used and clearly important system to balance the oxidation and antioxidant action in the body (see H. Sies, Oxidative Stress, pages. 2-4 1985). However, the native antioxidant capacity of the body is often insufficient to offset the ever-expanding activated oxides. In this case, the so-called "oxidative stress" will occur. 〇 The above-mentioned process of leaving equilibrium and biasing towards oxidation may involve two reasons: 1. The amount of activated oxygen metabolites generated exceeds the amount that the antioxidant system can carry; and 2. The capacity of the antioxidant system itself is insufficient. The results of the above cases are collectively referred to as "oxidation pressure." It is currently known that the above-mentioned deviation from equilibrium may be caused by many different diseases, such as inflammatory diseases such as hepatitis, central nervous system diseases such as epilepsy, or Parkinson's disease. Lung lesions such as asthma, psoriasis, side effects of anticancer drugs, chemical agents such as paraquats and side effects caused by radiation, and coronary circulation diseases such as cardiac infarction. Although not wishing to be bound by any theory, oxidative stress is still considered to be a factor in the disease and injury state of humans or other animals, and many studies have shown that even if oxidative stress is not the cause of the disease, It has a negative impact on the process that causes the disease, causing further damage to the cells of the diseased device 200940081. Current credible scientific evidence indicates that many physiological abnormalities and diseases in humans and other animals are associated with oxidative stress. Contains: aging: Accelerated aging that is faster than normal individuals. • Cardiac and heart disease: cardiotoxicily caused by atherosclerosis and adriamycin 〇❹ • kidney: kidney autoimmune syndrome (aut〇) Immmie nephritic syndromes) and heavy metal nephrotoxicity ° • solar radiation: skin wrinkling and pigmentation. Eye: cataractogenesis, degenerative retinal damage, aging macular degeneration. * lung (lung): lung cancer (initiation of withdrawal), emphysema, oxidant pollutants such as ozone and dioxin, bronchopulmonary dysphasia, asbestos carcinogenicity ). • nervous system disorders: Parkinson's disease, neuronal ceroid lipofuscinoses, Alzheimer's disease, muscular atrophy (music 8) 200940081 dystrophy), multiple sclerosis 〇 _ iron overload (ironoverload): idiopathic hemochromatosis, dietary overload, thalassemia, inflammation and immunity Inflammatory-immune injury: glomerulonephritis, autoimmune disease, rheumatoid arthritis 0 ❹ • liver (liver) · alcohol-induced liver damage (liver injuries) Induced by alcohol), halogenated hydrocarbons and paracetamol 〇 antioxidants provide protection because they can be used to remove active oxides before active oxides and free radicals cause molecular damage in living organisms. Free radical scavenging can also prevent the damage caused by oxidation from continuing to spread. A free radical chain reaction that breaks lipid peroxidation. The pathogenic state caused by the reaction of free radicals in the body and the degree of loading in the body, the so-called oxidative stress. In the past, the efficacy of antioxidants (radical scavengers) to eliminate oxidative stress in the above diseases has been studied, and an anti-inflammatory agent having a radical-eliminating effect has also been developed. Therefore, the effect of a substance having an antioxidant ability on reducing the oxidative pressure is obvious. Vitamins such as vitamin C and co-E are specially formulated in the daily diet and in the color of the nutritional supplements to help the body with low oxidative stress. More effective against sputum and active oxides is called anti-oxidation compound in the body of 200940081 itself. The antioxidant can provide electrons to the free radicals and cerium oxides, or block the normal configuration of free radicals and active oxides to terminate the dispersion of free and bound free radicals on the active oxide. The body's antioxidant defense system contains three important natural antioxidants: superoxide dismutase (SOD), catalase (CAT), and glutathiQne peiOxid^ GPX. . Study plus 'When the above antioxidant #1 participates in the reaction is metabolically continuous, the above antioxidants can work in concert, from the initial superoxide dismutase to the successive catalase and glutamine sulfur peroxidation Enzyme. In the absence of the above-mentioned superoxide dismutase, catalase and cholinylthioperoxidase, the antioxidant anti-purple system will easily receive the attack of oxidative stress and the antioxidant anti-oxidant system will produce The ability of superoxide dismutase, catalase and ethylamine thioperoxidase is closely related to aging and to inflammatory reactions, microbial or viral infections, cancer deterioration and systemic disorder of oracles, and other oxidative stresses, oxidation Pressure-induced, triggered by the pathological state of the strengthening of the north pressure of oxygen. Recently, there have been three main reasons for the interest in finding natural antioxidants (Dastmalchi, Dornian, Kosar, & Hiltunen, 2007): 1. Numerous clinical and epidemiological studies indicate that fruit and vegetable intake It is closely related to reducing the risk of chronic diseases such as cancer, cardiovascular disease and diabetes; 2. The safety concerns associated with the long-term intake of synthetic antioxidants by food or drink; and, 200940081 3. The public generally recognizes the consumption of natural and daily diets. The anti-caries agent is safer than the edible analog. Such recognition increases the propensity to use medicinal plants to obtain natural antioxidants. The antioxidant and anti-oxidative stress activities of chemical compounds derived from oil palm leaf extract have not been known. The present invention is intended to provide a novel oil palm leaf extract for reducing the oxidative stress in mammals and birds. The extract is rich in catechin gallate, ferulic acid, and phenolic acid © eg gallic acid and protocatechuic acid It has anti-oxidative stress activity, and the oil palm leaf extract combines catechin gallate, ferulic acid, and phenolic acid such as gallic acid ( The efficacy of gamc acid) and protocatechuic acid has not been proposed. In summary, 'the rich part of the oily leaf extract has been revealed, and the polyphenol-rich fraction is used as an anti-hypercholesterolemia and antihypertensive agent, but From the oil palm leaf extract, there are catechin gallate, feruiic aeid, and phenolic acid such as gallic acid and protocatechuic. The portion of acid has not been studied and disclosed, and the efficacy of the portion as an antioxidant pressure agent has not been studied and disclosed. SUMMARY OF THE INVENTION The main object of the present invention is to provide a composition derived from oil palm leaves and having therapeutic activity against mammals and birds. 200940081 The second object of the present invention is to provide a catechin gallate, a femlic add, and a phenolic add such as gallic acid and a genus Composition of pr〇t〇catechuic acid 0 A further object of the present invention is to provide a process for preparing an oil palm leaf extract. It is a further object of the present invention to provide a pharmaceutical composition comprising a novel extract and at least one pharmaceutically acceptable carrier. A further object of the present invention is to provide a pharmaceutical composition comprising novel extracts, stabilizers, carriers, excipients, extenders and other suitable materials. A further object of the present invention is to provide a composition comprising a novel extract which is intermingled with a pharmaceutically acceptable carrier and for reducing and avoiding oxidative stress in mammals and birds. In order to achieve the above object, the present invention provides a composition containing an oil palm leaf extract, characterized in that the extract comprises catechin gallate, ferulic acid and acid. (phenolic acid) such as; gallic acid and protocatechuic acid; and a method for producing catechin gallate, ferulic acid from oil palm leaves ( Ferulic acid) and a method for extracting phenolic acid such as gallic acid and pro-catechin (pr〇t〇catechuic acid), comprising the steps of: (a) drying or fresh The oil-swept leaves are mixed with water, alcohol, methanol, propylene glycol, ethyl acetate, acetal, isopropanol' or a mixture of the above solvents. 12 200940081 'or other polar solvent' is heated at a temperature of 25 to 95 degrees Celsius. 0. 5 hours to 96 hours to extract the vegetable liquid in the oil palm leaf; (b) filtering the plant liquid extracted in the above step a; (c) selectively filtering the plant liquid filtered in the above step b Contact with the adsorption chromatography medium of the component to retain the children in the vegetable solution Catechin gallate, ferulic acid, and phenolic acid such as gaiiic acid and protocatechuic acid © acid; the adsorption medium can be column adsorption Medium' or other adsorption medium; (9) using water, alcohol, methanol, acetone, ethyl acetate, chloroform, isopropanol, or a mixture of the above solvents, or other polar solvent, the part of the plant liquid adsorbed in the above step c Dissolving in the adsorption chromatography medium, and (e) drying the plant liquid obtained in the above step d using any of a dryer, a vacuum oven, a general oven, a microwave flooding box or a freeze dryer. SUMMARY OF THE INVENTION The object of the present invention is to provide a composition containing an effective amount of an individual which is in need of training, and which avoids the above-mentioned composition and avoids mammals and bird _ oxidative stress. [Embodiment] The present invention relates to a composition containing an oil palm leaf extract, characterized in that 'the extract contains catechin ga_, a 13 fernic acid, and a sour acid (phenolic acid) such as gallic acid and protocatechuic acid. The above oil grazing leaves are selected from the group consisting of Elaeis guineensis and Elaeisoleifera. The novel composition of the present invention contains 0.1% to 95% by weight of catechin gallate, and has a weight percent concentration of 〇1〇/〇 to 95% of fernlic acid. And a phenolic acid such as gallic acid and protocatechuic acid in a concentration of 0.1% to 95% by weight. In a preferred embodiment of the present invention, the above composition contains Catechin gallate, 0.5% to 10% by weight of catechin gallate, 1% to 5% by weight of ferulic acid, and 5% to 30% by weight Phenolic acid such as gaiiic acid and protocatechuic acid 〇 In a preferred embodiment of the present invention, the composition contains catechin gallate at a concentration of 0.5% by weight, fernic acid at a concentration of 1% by weight, and weight. A phenolic acid having a concentration of 20%, such as gallic acid and protocatechuic acid. The present invention also relates to a method for preparing an oil palm leaf extract, comprising the steps of: Mix dry or fresh oil palm leaves with water, alcohol, methanol, acetone, ethyl acetate, gas, isopropyl alcohol 'or a mixture of the above solvents' or other polar solvent, then 25 degrees Celsius to 95 degrees Celsius Heating at a temperature of 200940081 for 0.5 hours to 96 hours to extract the vegetable liquid in the oil palm leaf; (b) filtering the plant liquid extracted in the above step a; (c) selecting the plant liquid filtered in the above step b and optionally Contacting the adsorption medium of the adsorbent component to retain catechin gallate, fernlic acid, and phenolic acid such as gallic acid in the vegetable solution And protocatechuic acid; The adsorption medium may be a column adsorption medium, or other adsorption medium; (d) between 10 and 80 degrees 'pressure between 0.1 bar and 1 bar, using water, alcohol, methanol, acetone, ethyl acetate, a portion of the plant liquid adsorbed in the above step c is dissolved from the adsorption chromatography medium by a gas imitation, isopropanol, or a mixture of the above solvents, or other polar solvent to obtain a catechin-rich gallic acid. (catechin gallate), fercic acid (fcrulic acid) and phenolic acid (10) the add) such as; gallic acid and protocatechuic acid extract; and (e) spray The vegetable liquid obtained in the above step d is dried by a mist drying, a vacuum supply box, a general supply box, a microwave oven, a freeze dryer or any drying device. In a preferred embodiment of the present invention, in the extraction apparatus in which the oil-labeled leaves are mixed with the solvent, a damaged dry oil palm leaf is mixed with 5 parts by weight of solvent to extract; in a preferred embodiment, with 10 to 30 parts of solvent were extracted. In a preferred embodiment, the mixing time is from 丨 hours to 96 hours; in a preferred embodiment of 15 200940081, the mixing time is from 8 hours to 24 hours. In a preferred embodiment, the temperature of the solvent is maintained between 25 and 95 degrees Celsius; in a preferred embodiment, the temperature of the solvent is maintained between 50 and 6 degrees Celsius. In a preferred embodiment of the invention, the solvent used for extraction is selected from the group consisting of water, alcohol, methanol, acetone, ethyl acetate, chloroform, isopropanol or a mixture of the above solvents; in a preferred embodiment, It is selected from aqueous solutions of water, alcohol or alcohol; in another preferred embodiment, an aqueous alcohol solution containing 30% by weight of water and 70% by weight of alcohol is used. In a preferred embodiment of the present invention, the adsorption chromatography medium comprises styrene-divinylbezene eopolymei: resin, phenol-formakiehyde resin. , acrylic resin, methacrylate resin (methacryiateresir^ and polyamide resin). Examples of the above resins are: Amberlite XAD-1, Amberlite XAD of the company Rohm & Haas, Philadelphia, USA -2, Amberlite XAD-4, Amberlite XAD-7, Amberlite XAD-8, Amberlite XAD-11, Amberlite XAD-12, Amberlite

Q XAD-1180、Amberlite 7HP、Amberlite 761 和 Duolite S861 的樹脂；或選用日本東京三菱化學工業有限公司之型號為 Diaion HP-10' Diaion HP-20 ' Diaion HP-21 ' Diaion HP-30 ' DiaionHP-40和DiaionHP-5〇的樹脂；或選用中國天津南海 和成科學科技公司之型號為AB-8 Crosslinked polystyrene(交聯型聚苯乙烯）和 H103 Crosslinked polystyrene(交聯型聚苯乙烯)樹脂。 於本發明之一理想實施例中，該樹脂為苯乙稀-二乙稀 16 200940081 本共聚物樹^日(styrene-divinylbenzene copolymer resins)，其 生產及貿易名稱為AB-8 Crosslinked polystyrene(交聯型聚 苯乙烯’中國天津南海和成科學科技公司的產品)、Amberlite XAD-1180(美國費城R〇hm&Haas公司的產品）、 Amberlite7HP(美國費城R〇hm&Haas公司的產品）、 Amberlite76l(美國費城R〇hm&Haas公司的產品）。 於本發明之一較理想實施例中，該樹脂為苯乙烯-二乙 稀苯共聚物樹脂(styrene-divinylbenzene eopolymer· resins)， 其生產及貿易名稱為AB-8 Crosslinked polystyrene(交聯型 聚苯乙烯’AB-8’中國天津南海和成科學科技公司的產品）。 用以自吸附層析介質溶離該含有所欲保留化合物之植 物液之溶離溶劑可為水、酒精、甲醇、丙酮、乙酸乙酯、 氯仿、異丙醇，或上述溶劑之混合劑，或其他所屬技藝領 域117具有通常知識者習知之極性溶劑。較佳之溶劑為酒精 水/谷液。更佳之溶劑為漠度為3〇%的酒***溶液。 於本發明之一較佳實施例中，乾燥方式包含使用喷霧 式乾燥器、真空烘箱、普通烘箱。其中以使用噴霧式乾燥 器為較佳。 本發明用以製備油棕葉萃取物之設備，即本發明用以 製備非洲油掠(Elaeis guineensis)和美洲油棕(Elaeis oleifera) 之萃取物的系統’包含：藥草萃取槽、吸附層析管柱和乾 燥裝置。 根據本發明之一態樣，該藥草萃取槽設有一蒸汽套以 及一用以攪拌槽内物質之高速攪拌器。蒸氣藉由該蒸氣套 17 以將槽内物質加熱。油棕葉與水、酒精、甲醇、丙酮、乙 酸乙酯、氣仿、異丙醇、或上述溶劑之混合劑、或所屬技 藝領域中具有通常知識者習知之極性溶劑於藥草萃取槽中 相互混合並加熱於較佳溫度範圍攝氏25度至95度達1小 時至96小時。此加熱步驟產生一藥草萃取液，該萃取液接 著經過濾程序後再加以收集。 根據本發明之一態樣，該吸附層析管柱填充以吸附層 析樹脂’該樹脂較佳為聚苯乙烯樹脂(p〇lystyrene此咖）。接 者將過渡後的藥草萃取液通入吸附層析管柱，藉此將兒茶 素沒食子酸(catechin gallate)、阿魏酸(ferulic acid)以及酚酸 (phenolic acid)如沒食子酸(gallic acid)和原兒茶酸 (protocatechuicacid)吸附於所述樹脂的表面。所述含有兒茶 素沒食子酸(catechin gallate)、阿魏酸(fernlic acid)以及酚酸 (phenolic acid)如沒食子酸（gallic acid)和原兒茶酸 (protocatechuicacid)之萃取液部份接著以水、酒精、甲醇、 丙酮、乙酸乙酯、氯仿、異丙醇、或上述溶劑之混合劑、 或其他極性溶劑自吸附層析管柱中溶離出來。該含有所欲 保留成份之藥草液體最後以喷霧式乾燥器、真空烘箱、普 通烘箱、微波烘箱、冷凍乾燥器或任一種所屬技藝領域中 具有通常知識者習知之乾燥裝置乾燥。 本發明之油棕葉萃取物確認有兒茶素沒食子酸 (catechin gallate)、阿魏酸(ferulic acid)以及沒食子酸(gallic acid)的定性測試。 以高效能液態層析法(HPLC)測定油棕葉萃取液中含有 兒茶素沒食子酸(catechingallate): a·將1毫克的兒茶素沒食子酸(catechin gallate)溶於1 毫升之濃度為0.1%的磷酸中以製備兒茶素沒食子 酸的標準指示溶液； b·將200毫克之本發明萃取物溶於10毫升的酒精以製 備待測定溶液； c.分別將上述兩溶液注入高效能液態層析法系統 (HPLC)，而其實驗材料與參數為： •設備·· Perkin Elmer液態層析(機型序號為2〇〇 LC)； 鲁管枉：SinochromODS-BPcolumn(250 公釐乘 4.6 公釐之内徑，顆粒大小為5微米）； _移動相：體積百分濃度2%的乙酸和乙睛之混合 液； 鲁於50分鐘内以線性梯度使用不同濃度之溶劑混 合液自92%經8%再提高至31% ; ❿流速：每分鐘1.0毫升；以及， *偵測：波長280奈米之紫外光。 由標準指示溶液和待測定溶液之層析圖譜顯示，於流 滯時間28分鐘時呈現一個符合兒茶素沒食子酸(catechin gallate)的主要波峰。存在該波峰即確認於本發明中存在有 兒茶素沒食子酸(catechingallate)的成份。 以薄膜液態層析法(TLC)測定油掠葉萃取液中含有阿 魏酸(femlic acid): 200940081 a. 將本發明萃取物溶於高效能液態層析法(HPLC)等 級之曱醇，接著以每分鐘4〇〇〇轉的速度離心15分 鐘’再提取上澄清液以作為待測定液； b. 使用甲醇/水之混合液(比例為7比1)作為展開劑， 將待測定液和阿魏酸(ferulic acid)指示標準液點於預 塗佈矽膠60(silica gel 60)之薄膜液態層析法薄層(薇 牌：E-Merck); c·風乾該薄層後，再以波長254奈米的紫外光觀察。 〇 待測定液和指示標準液皆可觀察到符合阿魏酸(ferulic acid)的淡紫色指示區域。存在該淡紫色指示區域即確認本 發明中存在有阿魏酸(ferulic acid)的成份。 以高效能液態層析法(HPLC)測定油棕葉萃取液中含有 沒食子酸(gallic acid): a. 將10毫克的沒食子酸(gallic acid)溶於10毫升的甲 醇中以製備兒茶素沒食子酸的標準指示溶液； b. 將200毫克之本發明萃取物溶於10毫升的甲醇以製 ® 備待測定溶液；以及， c·分別將上述兩溶液注入高效能液態層析法系統 (HPLC)，而其實驗材料與參數為： 鲁設備：Perkin Elmer液態層析(機型序號為200 LC)； •管柱：Hypersil BDS碳18管柱(250公釐乘4.6公 釐之内徑，顆粒大小為5微米）； 籲移動相：甲醇、水和磷酸之混合液（比例為 20 200940081 20:79.9:0.1); •流速：每分鐘1.0毫升；以及， 籲摘測：波長270奈米之紫外光。 由標準指示溶液和待測定溶液之層析圖譜顯示，於流 滯時間6.6分鐘時呈現一個符合沒食子酸(gaUic acid)的主要 波峰。存在該波峰即確認於本發明中存在有沒食子酸(gallic acid)的成份。 本發明之油棕葉萃取物所含之兒茶素沒食子酸 〇 (catechingallate)和阿魏酸(ferulic acid)的定量測試。 以高效能液態層析法(HPLC)定量油棕葉萃取液中所含 之兒茶素沒食子酸(catechin gallate)之方法包含以下步驟： a·將1毫克的兒茶素沒食子酸(catechin gallate)溶於1 毫升之濃度為0.1%的磷酸中以製備兒茶素沒食子 酸的標準指示溶液； b·將200毫克之本發明萃取物溶於1〇毫升的酒精以製 備待測定溶液； 〇 c.分別將上述兩溶液注入高效能液態層析法系統 (HPLC)，而其實驗材料與參數為： ♦設備：Perkin Elmer液態層析(機型序號為200 LC)； 籲管柱：Sinochrom ODS-BP column(250 公釐乘 4.6 公釐之内徑，顆粒大小為5微米）； 籲移動相：體積百分濃度2%的乙酸和乙睛之混合 液； 21 200940081 ♦於50分鐘内以線性梯度使用不同濃度之溶劑混 合液自92%至8% ; ♦流速：每分鐘1.0毫升； 鲁偵測：波長280奈米之紫外光；以及， •注入體積：20微升。 判讀高效能液態層析法系統(HPLC)之實驗數據於流滯 時間28分鐘時’得到一個屬於兒茶素沒食子酸(catechin gallate)的峰面積。 ® 藉由與標準指示溶液所含之兒茶素沒食子酸(catechin gallate)相比較，以判讀待測定溶液中兒茶素沒食子酸 (catechin gallate)的含量。利用以下公式計算待測定溶液中兒 茶素沒食子酸(catechingallate)的含量： 1000Crt/Wrs 其中： C代表由操作標準曲線(working standard curve)計算所 ❹ 得待測定液之兒茶素沒食子酸(catechin gallate)濃度(毫克/ 毫升）。 W代表用以製備待測定溶液之樣品重量(毫克）。 rt代表由待測定溶液所得之兒茶素沒食子酸(catechin gallate)峰面積。 rs代表由標準指示溶液所得之兒茶素沒食子酸(catechin gallate)峰面積。 以高效能液態層析法(HPLC)定量油棕葉萃取液中所含 之阿魏酸(ferulicacid)之方法： 22 2〇〇94〇〇8j a. 將阿魏酸(ferulic acid)溶於濃度為7〇〇/。的酒精中以製 備四種已知濃度為0.15毫克/毫升、0.20毫克/毫升、 0_25毫克/毫升和〇.5亳克/毫升的阿魏酸(feruiic ac沾) 的標準指不溶液； b. 將10毫克之本發明油棕葉萃取物容於1〇毫升的 70%酒精中以製備待測定溶液； c. 分別將上述兩溶液注入高效能液態層析法系統 〇 (HPLC) ’而其實驗材料與參數為： •設備：Perkin Elmer液態層析(機型序號為200 LC)； •管柱：Hypersil BDS碳18管柱(250公釐乘4.6公 釐之内徑’顆粒大小為5微米）； •移動相：曱醇和0.1%碌酸的混合液(30 : 70); •流速：每分鐘1.0毫升； 鲁摘測：波長325奈米之紫外光；以及， ® •注入體積：20微升。 判讀高效能液態層析法系統(HPLC)之實驗數據於流滯 時間28.8分鐘時’得到一個屬於阿魏酸(ferulic acid)的峰面 積。 藉由與標準指示溶液所含之阿魏酸(fernlic acid)相比 較’以判讀待測定溶液中阿魏酸(ferulic acid)的含量。利用 以下公式計算待測定溶液中阿魏酸(ferulic acid)的含量： 1000Crt/Wrs 其中： 23 200940081 c代表由實驗中標準指示溶液所得之操作標準曲線 (wOTking standard curve)計算所得之阿魏酸(feruHc acid)的濃 度(毫克/毫升)。 W代表用以製備待測定溶液之樣品重量(毫克）。 I*t代表由待測疋溶液所得之阿魏酸(feruiic a(Jid)峰面積。 rs代表由標準指示溶液所得之阿魏酸(fcmlic add)蜂面 積。 以紫外光光譜儀定量本發明之油棕葉萃取物中酚酸 ❹ （phenolic acid)之總含量。 一個用以定量本發明之油棕葉萃取物中酚酸(phenolic acid)之總含量的方法包含以下步驟： a.將1〇.〇宅克的原兒茶酸(protocatechuic acid)溶於100 毫升的HPLC等級之曱醇以製備標準指示溶液；再 將所得溶液以1比9的比例用HPLC等級之曱醇稀 釋； 0 b.將10毫克之本發明萃取物容於1〇毫升的7〇%酒精 中以製備待測定溶液； c.將 9〇 毫克的鐵氰化卸(potassium ferricyanide，赤jk 鹽)溶於10毫升的純水中以製備濃度為0.9%的鐵氰 化卸(potassium ferricyanide)水溶液； 丄將90毫克的氯化鐵(ferric chloride)溶於10毫升的純 水中以製備濃度為0.9%的氯化鐵(ferric chloride)水 溶液；以及， e.混合 9 毫升的 〇·9%鐵氰化鉀(potassium ferricyanide) 24 200940081 水溶液和〗0毫升的0.9%的氯化鐵(ferric chloride)水 ’谷液以製備顯色試劑reagent) 〇 將所有溶液(標準指示溶液、待測定溶液和空白溶液) 放於暗室中5分鐘。將所有溶液以0.1莫耳濃度之鹽酸水溶 液調配至一定體積並混合均勻，再放置於暗室中分鐘。 以空白溶液絲準’晰標絲示驗和待歌溶液於波 長679奈求光源的吸光值。以標準指示溶液之濃度為X抽， 且吸光值為Y _輕—標料算鱗。依_標準計算 曲線計算盼酸(phenolic acid)之總濃度。 利用下述公式計算待測定溶液中酴酸恤n〇lic咖)之 總濃度並以百分比(％)呈現： 50,000 C/W 其中： c代表由實驗巾標準指祕賴得之操作標準曲線 (working standard curve)計算所得之酚酸⑽咖此add)之總 濃度(毫克/毫升）。 一 W代表用以製備待測定溶液之樣品重量(毫克）。 本發明包括-具有依據本發明所製備之萃取物的醫療 組合物，其中，該組合物之形式為茶飲、藥片、膜衣鍵’、、 錠劑“且嚼錠、膠囊，軟膠囊、顆粒劑、膜衣顆粒劑、散 劑、膜衣散劑、驗、賴、乳液顯浮劑之形式以供人 類或其他動物使用以降低或避免氧化壓力。 更甚之’本發明包括-醫藥組合物，合物具有所 述萃取物之有效成份如1毫克至800毫克；以3〇〇 ^克至 25 200940081 500毫克為佳，以及一醫藥可接受的載體。 本發明提供一種具有新穎萃取物之醫藥組合物配製為 口服的、經口頰的、經直腸的或經皮膚的或其他適合經口 或鼻吸入或喷入之投藥形式。 以口服投藥形式，該醫藥組合物之形式可為茶飲、藥 片、膜衣錠、鍵劑、呕嚼錠、膠囊，軟膠囊、顆粒劑、膜 衣顆粒劑、散劑、膜衣散劑、藥液、糖漿、乳液或懸浮劑， 經習用方法魏m含s藥T触之卿_xeipient)如黏 〇 合劑(如’膠化澱粉、聚乙烯吡咯烷酮Φ〇1γνίηγΐΓΓ〇1Μ〇η^或 1½丙基甲基纖維素(hydroxypropyl methylcellulose));填充劑 (如’乳糖、微晶纖維素(microcrystallijje cellul〇s)、殿粉或礙 酸鈣(tricaldmn phosphate));潤滑劑（如，硬脂酸鎂 (magnesium stearate)、滑石粉(taic)或氧化石夕(础ca));崩散劑 (如’交聯型聚乙烯吡咯烷酮（cr〇ss_linked polyvinylpyrrolidone)、交聯羧甲基纖維素鈉(cr〇ss carmdbse 〇 sodium)或羧甲澱粉鈉(sodium starch glyc〇iate));或濕潤劑 (如，十二烷基硫酸鈉(s〇diumlaulylsulphate))。該錠劑可經 所屬技藝領域中習用技術形成膜衣。 以溶液配方經口服投藥的例子為藥液、糖漿、乳液或 懸浮劑，或以乾燥成品呈現，再於使用前溶於水或其他溶 媒t。該溶液配方以習知方式製備並佐以醫藥可接受的添 加劑如懸浮劑(如，山梨醇糖漿、纖維素衍生物或氫化食用 脂）；乳化劑(如，印磷脂或***膠）；非水相溶媒(如，杏 仁油、油性酯、乙醇或植物性調和基礎油）；以及防腐劑(如， 26 200940081 對羥基苯甲酸甲酯(methyl-hydroxybenzoates)、對羥基苯甲 酸丙酯(propyl-p_hydroxybenzoates)或山梨酸(sorbic acid)) 〇 S亥溶液配方也可酌情添加緩衝鹽類、香料、色素和甜味劑。 經口服投藥之配方可適當調製以控制或延長本發明萃 取物釋放之時間。經口頰投藥之組合物可以習知方式調製 為樂片或键劑。 本發明之醫藥組合物可調製為供鼻腔喷入劑和口腔吸 入劑。所述投藥方式之配方形式的例子包含喷劑和霧劑以 ❹ 觀人或噴人。外狀皮膚轉配方可佐雌何所屬技藝 領域中具有通常知識者習知適用之乳霜、軟膏或乳液基質。 本發明之醫藥組合物可調製為經直腸投藥之組合物如 检劑或灌_ ’翻是含有習知栓細基質如可可脂或其 他油脂類物質。 於本發明之-較佳實施例，該醫藥組合物，包括膠囊、 軟膠囊或㈣丨’含有1%至％%之所述萃取物，以及1%至 〇 95%之醫藥可接受的載體。 醫藥可接受的載體”一詞意指至少一相容之固體或 液體填充稀_ ’或其他所屬技藝領射具有通常知識者 習知之醫藥用賦形劑。 做為醫藥可接受的載體之物質的例子為乳糖、葡萄 糖、蔗糖、澱粉如玉米澱粉和馬鈐薯澱粉、纖維素衍生物 如羧甲基纖維素鈉(sodium carboxymethylcellulose)、醋酸纖 維素(cellulose acetate)以及微晶纖維素(micr〇CIyStaiune cellulose) 〇 27 200940081 本發明之組成物施與人類(體重約60公斤者)之合適劑 量為0.1毫克至1公克’如每一單位劑量以淨重標示具有1 毫克至500毫克之有效成份。一天施與單位劑量如丨至4 次。實施劑量係配合給藥方式。合適的是也視患者之年齡、 體重以及病情之輕重來定期調整施與之劑量。確切的劑量 與投藥途徑根本上仍遵行所屬醫師或獸醫的判斷。 依據本發明所製備之萃取物於生體外試驗(加vz>〇)模 型中，展現了抗氧化能力以及清除自由基的功效，且於生 體内試驗(加Wvo)模型中展現了抗氧化壓力之功效。 依據本發明之另一實施例中，於需要治療之哺乳類和 鳥類個體投以足夠活性劑量之組合物，該萃取物得以降低 或避免其氧化壓力。 承後所述為根據本發明所製備之組合物的幾個例子。 於本發明組合物所實行之毒性測試註明了，實驗大鼠 (Spmgue-Dawley rats) 口服施與每公斤體重3〇克的萃取物之 劑量下，該萃取物不具任何毒性。 據此，人類每公斤體重一天口服施與〇〇3克的油棕葉 萃取物被認定為合適且安全的。 實例一 油棕葉萃取物之製備 大約50克之乾燥油棕葉與5〇〇毫升之水/酒精混合液 (體積比例3 : 7)混合並萃取於攝氏60度至65度之溫度約 60分鐘。所付聚液接著經雙層麻紗布扣仍此也也)過渡以產 28 200940081 生502克之原萃取液。 所得之原萃取液接著注入管柱吸附層析裝置。 管柱(内控5.0公分，長度4〇公分)内填充有Amberlite XAD16HP樹脂(R0hm&hass公司生產)使管柱容積為約78〇 毫升。該管柱以4至5倍管柱體積之去離子水清洗。以幫 浦將前述萃取步驟所得之原萃取液注入管柱中。該管柱首 先經1500毫升之去離子水溶離鹽類、醣類和其他不欲保留 之親水性物質。 該管柱接著於穩定流速為每分鐘25毫升、工作溫度為 攝氏60度及壓力0.5至1巴之條件下，以15〇〇毫升的水/ 異丙醇混合液(體積比例為3:7)溶離得到一富含兒茶素沒食 子酸(catechin gallate)、阿魏酸(fcruiic acid)以及酚酸(phenolic acid)如沒食子酸(gallic acid)和原兒茶酸(protocatechuic acid) 的純化萃取液體。所得之萃取液體進一步於旋轉蒸發機 (rotary evaporator)中濃縮至50毫升，再將該濃縮液放置於 攝氏60度之真空烘箱乾燥八個小時。 所得之2.52克的米黃色粉末含有以下成份： 兒茶素沒食子酸(catechin gallate)成份-1.1%(經高效能 液態層析法測量） 阿魏酸(fernlic acid)成份-1.5%(經高效能液態層析法測 量） 總酚酸(total phenolic acids)成份-10.2%(經紫外光光譜 儀測量） 29 200940081 油棕葉萃取物之製備 100公斤之新鮮油棕葉經裁切為長度約2公分之小片後 放入萃取槽。加入1000公升的水/異丙醇混合液(體積比例 為3 : 7)並於攝氏60度加熱8小時。 經具ίο微米孔洞之濾、筒(cartridge filter)過滤以使原萃 取液與葉片分離。該過濾後之液體於攝氏7〇度，經〇〇8_〇 〇9 百萬帕斯卡(MPa)之減壓濃縮以得約2〇〇公升的濃縮萃取液 © (密度為每立方公分1.10至1.20克；)。 所得濃縮萃取液接著注入吸附層析管柱，該管柱為直 徑15公分且長度150公分之不鏽鋼管柱。該管柱係以聚醯 胺樹脂(polyamide resin)填充，且顆粒尺寸範圍為3〇至6〇 篩孔。 該管柱接著以200公升的去離子水清洗，並接著於穩 定流速每分鐘1.5公升、工作溫度攝氏20至3〇度且壓力為 ❹ 0.5巴至1巴之條件下，以2〇〇公升之水/異丙醇混合液(體 積比例為3 : 7)溶離得到一富含兒茶素沒食子酸(catechin gallate)、阿魏酸(feruiic娜以及酚酸(phen〇lic add)如沒食 子酸(gallic acid)和原兒茶酸(protocatechuic acid)的純化萃取 液體。所得萃取液體接著以喷霧式乾燥器乾燥。該喷霧式 乾燥器之進氣溫度(inlet temperature)設定為約攝氏17〇度至 180度’且出氣溫度(outlettemperature)設定為約攝氏度 至105度。 所得之12.5公斤的米黃色粉末含有以下成份： 30 200940081 兒茶素沒食子酸(catechin gallate)成份-1 · 15%(經高效能 液態層析法測量） 阿魏酸(fernlic acid)成份-1.6%(經高效能液態層析法測 量） 總紛酸(total phenolic acids)成份-10.5%(經紫外光光譜 儀測量） 藉定量及定性分析以進行本發明組成物之特性分析。 以薄膜液態層析法(Thin Layer Chromatography，TLC) 〇 和高效能液態層析法（High Performance LiquidQ XAD-1180, Amberlite 7HP, Amberlite 761 and Duolite S861 resin; or selected from Japan Tokyo Mitsubishi Chemical Industries Co., Ltd. as Diaion HP-10' Diaion HP-20 ' Diaion HP-21 ' Diaion HP-30 ' DiaionHP- 40 and Diaion HP-5 〇 resin; or selected from China's Tianjin Nanhai Hecheng Science and Technology Company as AB-8 Crosslinked polystyrene (crosslinked polystyrene) and H103 Crosslinked polystyrene (crosslinked polystyrene) resin. In a preferred embodiment of the present invention, the resin is styrene-divinylbenzene copolymer resins, and its production and trade name is AB-8 Crosslinked polystyrene (crosslinking). Polystyrene 'product of Tianjin Nanhai Hecheng Science and Technology Co., Ltd.), Amberlite XAD-1180 (product of R〇hm & Haas, Philadelphia, USA), Amberlite 7HP (product of R〇hm & Haas, Philadelphia, USA), Amberlite76l ( Products of R〇hm & Haas, Philadelphia, USA). In a preferred embodiment of the present invention, the resin is styrene-divinylbenzene eopolymer·resin, and its production and trade name is AB-8 Crosslinked polystyrene (crosslinked polystyrene). Ethylene 'AB-8' China Tianjin Nanhai Hecheng Science and Technology Company's products). The solvent for dissolving the plant liquid containing the desired compound from the adsorption chromatography medium may be water, alcohol, methanol, acetone, ethyl acetate, chloroform, isopropanol, or a mixture of the above solvents, or other The field of art 117 has a polar solvent that is conventionally known to those skilled in the art. The preferred solvent is alcohol/cold. A more preferred solvent is an aqueous alcohol solution having an indifference of 3% by weight. In a preferred embodiment of the invention, the drying means comprises the use of a spray dryer, a vacuum oven, a conventional oven. Among them, a spray dryer is preferred. The apparatus for preparing an oil palm leaf extract of the present invention, that is, the system for preparing an extract of Elaeis guineensis and Elaeis oleifera of the present invention comprises: a herb extracting tank, an adsorption chromatography tube Column and drying unit. According to one aspect of the invention, the herb extraction tank is provided with a steam jacket and a high speed agitator for agitating the contents of the tank. The vapor is used to heat the contents of the tank by the vapor jacket 17. Oil palm leaves mixed with water, alcohol, methanol, acetone, ethyl acetate, gas, isopropyl alcohol, or a mixture of the above solvents, or a polar solvent known to those skilled in the art, in a herb extraction tank And heating at a preferred temperature range of 25 degrees Celsius to 95 degrees for 1 hour to 96 hours. This heating step produces a herb extract which is collected after the filtration process. According to an aspect of the present invention, the adsorption chromatography column is filled with an adsorption chromatography resin. The resin is preferably a polystyrene resin. The recipient passes the transitioned herb extract into the adsorption chromatography column, thereby using catechin gallate, ferulic acid, and phenolic acid such as gallnuts. Galic acid and protocatechuic acid are adsorbed on the surface of the resin. The extract liquid containing catechin gallate, fernlic acid, and phenolic acid such as gallic acid and protocatechuic acid The fraction is then eluted from the adsorption chromatography column with water, alcohol, methanol, acetone, ethyl acetate, chloroform, isopropanol, or a mixture of the above solvents, or other polar solvent. The herb liquid containing the desired retention component is finally dried in a spray dryer, vacuum oven, conventional oven, microwave oven, freeze dryer or any of the drying devices known to those skilled in the art. The oil palm leaf extract of the present invention was confirmed to have qualitative tests of catechin gallate, ferulic acid, and gallic acid. Determination of catechin gallate in oil palm leaf extract by high performance liquid chromatography (HPLC): a· Dissolve 1 mg of catechin gallate in 1 ml a concentration of 0.1% phosphoric acid to prepare a standard indicator solution for catechin gallate; b. 200 mg of the extract of the present invention is dissolved in 10 ml of alcohol to prepare a solution to be determined; c. The solution is injected into a high performance liquid chromatography system (HPLC), and the experimental materials and parameters are: • Equipment · Perkin Elmer liquid chromatography (model number is 2〇〇LC); Lu Guanxi: SinochromODS-BPcolumn (250 Membrane by 4.6 mm inner diameter, particle size 5 μm); _ mobile phase: 2% by volume of acetic acid and acetonitrile mixture; Lu is mixed with different concentrations of solvent in a linear gradient within 50 minutes The liquid was increased from 92% to 8% by 8%; ❿ flow rate: 1.0 ml per minute; and, * detection: ultraviolet light with a wavelength of 280 nm. A chromatogram of the standard indicating solution and the solution to be determined showed a major peak corresponding to catechin gallate at 28 minutes of the lag time. The presence of this peak confirms the presence of a component of catechin gallate in the present invention. Determination of femlic acid in oil swept leaf extract by thin film liquid chromatography (TLC): 200940081 a. Dissolve the extract of the present invention in high performance liquid chromatography (HPLC) grade sterol, followed by Centrifuge at a speed of 4 rpm for 15 minutes to re-extract the supernatant to be used as the solution to be measured; b. Use a mixture of methanol/water (7 to 1 ratio) as the developing solvent, and the solution to be measured and Ferulic acid indicates that the standard solution is applied to a thin film liquid chromatography thin layer of pre-coated silica gel 60 (Wei brand: E-Merck); c·air-dried the thin layer and then wavelength Ultraviolet light observation of 254 nm.淡紫色 The lavender indicating area conforming to ferulic acid can be observed in both the liquid to be measured and the indicator standard. The presence of the lavender indicating region confirms the presence of ferulic acid in the present invention. Determination of gallic acid in oil palm leaf extract by high performance liquid chromatography (HPLC): a. Prepare 10 mg of gallic acid in 10 ml of methanol to prepare a standard indicator solution of catechin gallic acid; b. 200 mg of the extract of the invention is dissolved in 10 ml of methanol to prepare a solution to be determined; and c. respectively injecting the above two solutions into a high-performance liquid layer Analytical system (HPLC), and its experimental materials and parameters are: Lu equipment: Perkin Elmer liquid chromatography (model number is 200 LC); • Column: Hypersil BDS carbon 18 column (250 mm by 4.6 mm) Inner diameter, particle size 5 microns); Call mobile phase: a mixture of methanol, water and phosphoric acid (ratio 20 200940081 20:79.9:0.1); • Flow rate: 1.0 ml per minute; and, call for measurement: wavelength 270 nm of ultraviolet light. A chromatogram of the standard indicating solution and the solution to be measured showed a major peak corresponding to gaUic acid at a flow time of 6.6 minutes. The presence of this peak confirms the presence of a gallic acid component in the present invention. Quantitative testing of catechinal gallate and ferulic acid contained in the oil palm leaf extract of the present invention. The method for quantifying catechin gallate contained in oil palm leaf extract by high performance liquid chromatography (HPLC) comprises the following steps: a·1 mg of catechin gallic acid (catechin gallate) is dissolved in 1 ml of 0.1% phosphoric acid to prepare a standard indicator solution of catechin gallate; b. 200 mg of the extract of the present invention is dissolved in 1 ml of alcohol to prepare Measuring solution; 〇c. Injecting the above two solutions into a high performance liquid chromatography system (HPLC), and the experimental materials and parameters are: ♦ Equipment: Perkin Elmer liquid chromatography (model number is 200 LC); Column: Sinochrom ODS-BP column (250 mm by 4.6 mm inner diameter, particle size 5 μm); Call mobile phase: 2% by volume of acetic acid and acetonitrile mixture; 21 200940081 ♦ at 50 A mixture of solvents at different concentrations in a linear gradient from 92% to 8% in minutes; ♦ Flow rate: 1.0 ml per minute; Lu detection: UV light with a wavelength of 280 nm; and, • Injection volume: 20 μl. The experimental data of the high performance liquid chromatography system (HPLC) was judged to give a peak area belonging to catechin gallate at a lag time of 28 minutes. The content of catechin gallate in the solution to be assayed is determined by comparison with catechin gallate contained in the standard indicator solution. Calculate the content of catechin gallate in the solution to be determined by the following formula: 1000Crt/Wrs where: C represents the catechin consumption of the solution to be determined by the working standard curve The concentration of catechin gallate (mg/ml). W represents the weight (mg) of the sample used to prepare the solution to be tested. Rt represents the catechin gallate peak area obtained from the solution to be tested. Rs represents the catechin gallate peak area obtained from the standard indicator solution. Method for quantifying ferulic acid contained in oil palm leaf extract by high performance liquid chromatography (HPLC): 22 2〇〇94〇〇8j a. Dissolving ferulic acid in concentration It is 7〇〇/. In the preparation of four known concentrations of ferulic acid (feruiic ac) of four known concentrations of 0.15 mg / ml, 0.20 mg / ml, 0 25 mg / ml and 〇 5 g / ml; b. 10 mg of the oil palm leaf extract of the present invention was placed in 1 ml of 70% alcohol to prepare a solution to be determined; c. The above two solutions were respectively injected into a high performance liquid chromatography system (HPLC) and the experiment was carried out. Materials and parameters are: • Equipment: Perkin Elmer liquid chromatography (model number 200 LC); • Column: Hypersil BDS carbon 18 column (250 mm by 4.6 mm inner diameter 'particle size 5 microns) • Mobile phase: a mixture of decyl alcohol and 0.1% citric acid (30: 70); • Flow rate: 1.0 ml per minute; Lu smeared: UV light with a wavelength of 325 nm; and, ® • Injection volume: 20 μl . The experimental data of the high performance liquid chromatography system (HPLC) was judged to give a peak area belonging to ferulic acid at a lag time of 28.8 minutes. The content of ferulic acid in the solution to be tested is judged by comparing with the fernlic acid contained in the standard indicating solution. Calculate the content of ferulic acid in the solution to be determined by the following formula: 1000Crt/Wrs where: 23 200940081 c represents the ferulic acid calculated from the operating standard curve obtained from the standard indicating solution in the experiment ( The concentration of feruHc acid) (mg/ml). W represents the weight (mg) of the sample used to prepare the solution to be tested. I*t represents the feruiic a (Jid) peak area obtained from the ruthenium solution to be tested. rs represents the fcmlic add bee area obtained from the standard indicating solution. The oil of the present invention is quantified by ultraviolet spectrometer The total content of phenolic acid in the palm leaf extract. A method for quantifying the total content of phenolic acid in the oil palm leaf extract of the present invention comprises the following steps: a. Protocatechuic acid is dissolved in 100 ml of HPLC grade sterol to prepare a standard indicator solution; the resulting solution is diluted with HPLC grade sterol in a ratio of 1 to 9; 0 b. 10 mg of the extract of the present invention is contained in 1 ml of 7 wt% alcohol to prepare a solution to be determined; c. 9 g of ferric cyanide dissolving (potassium ferricyanide, red jk salt) is dissolved in 10 ml of pure water To prepare a 0.9% aqueous solution of potassium ferricyanide; 丄 90 mg of ferric chloride dissolved in 10 ml of pure water to prepare ferric chloride at a concentration of 0.9% (ferric) Chloride); and, e. Mix 9 ml of 〇·9% iron Potassium ferricyanide 24 200940081 Aqueous solution and 0 ml of 0.9% ferric chloride water solution to prepare reagent reagents 〇All solutions (standard indicator solution, solution to be determined and blank solution) ) Put it in the darkroom for 5 minutes. All solutions were prepared in a 0.1 molar aqueous solution of hydrochloric acid to a volume and mixed well, and then placed in a dark room for a minute. The blank solution was used to determine the absorbance of the light source at the wavelength of 679. The concentration of the solution is indicated by X as the standard, and the absorbance is Y_light-standard scale. Calculate the total concentration of phenolic acid according to the _ standard calculation curve. Use the following formula to calculate the total concentration of citrate in the solution to be determined and present in percentage (%): 50,000 C/W where: c represents the operating standard curve obtained by the standard of the test towel (working Standard curve) Calculate the total concentration of phenolic acid (10) added (mg/ml). One W represents the weight (mg) of the sample used to prepare the solution to be tested. The invention comprises a medical composition having an extract prepared according to the invention, wherein the composition is in the form of a tea, a tablet, a film coat, a tablet, and a chewable tablet, a capsule, a soft capsule, a granule In the form of a granule, a granule, a powder, a granule, a granule, a granule, a lotion, a lotion, or a lotion for use in humans or other animals to reduce or avoid oxidative stress. More specifically, the present invention includes a pharmaceutical composition. The active ingredient of the extract is, for example, 1 mg to 800 mg; preferably 3 gram to 25 200940081 500 mg, and a pharmaceutically acceptable carrier. The present invention provides a pharmaceutical composition having a novel extract. Formulated as an oral, buccal, rectal or transdermal or other form suitable for oral or nasal inhalation or insufflation. In the form of oral administration, the pharmaceutical composition may be in the form of tea, tablets, Membrane ingot, key, chewable ingot, capsule, soft capsule, granule, film granule, powder, film coating powder, liquid, syrup, emulsion or suspending agent, by conventional method Wei m containing s medicine T touch Qing_ Xeipient) such as adhesives (such as 'gelatinized starch, polyvinylpyrrolidone Φ〇1γνίηγΐΓΓ〇1Μ〇η^ or 11⁄2 propylpropylmethylcellulose (hydroxypropyl methylcellulose)); fillers (such as 'lactose, microcrystalline cellulose ( Microcrystallijje cellul〇s), temple powder or tricaldmn phosphate; lubricant (eg magnesium stearate, talc or oxidized stone); disintegrating agent Such as 'cross-linked polyvinylpyrrolidone (cr〇ss_linked polyvinylpyrrolidone), croscarmellose sodium (cr〇ss carmdbse 〇sodium) or sodium starch glyc〇iate); or wetting agent (such as Sodium dodecyl sulfate (s〇diumlaulylsulphate). The tablet may be formed into a film coat by conventional techniques in the art. Examples of oral administration in solution formulations are liquids, syrups, emulsions or suspensions, or The dried product is presented and dissolved in water or other solvent t prior to use. The solution formulation is prepared in a conventional manner and is formulated with pharmaceutically acceptable additives such as suspending agents (eg, sorbitol syrup, cellulose derivatives or hydrogenated edible fats) Emulsifier (eg, phospholipid or gum arabic); non-aqueous solvent (eg, almond oil, oily ester, ethanol or botanical blend base oil); and preservative (eg, 26 200940081 methylparaben ( Methyl-hydroxybenzoates, propyl-p-hydroxybenzoates or sorbic acid 〇S solutions can also be added with buffer salts, flavors, colors and sweeteners as appropriate. Formulations for oral administration can be suitably formulated to control or prolong the release of the extract of the present invention. The composition for buccal administration can be prepared in a conventional manner as a tablet or a key. The pharmaceutical composition of the present invention can be formulated into a nasal injecting agent and an oral inhaling agent. Examples of the formulation form of the administration method include a spray and an aerosol to smear or spray. The external skin transfer formulation can be applied to a cream, ointment or lotion base which is conventionally known to those skilled in the art. The pharmaceutical composition of the present invention can be formulated into a composition for rectal administration such as a test or a medicinal substance containing a conventional fine matrix such as cocoa butter or other oils and fats. In a preferred embodiment of the invention, the pharmaceutical composition comprises a capsule, a soft capsule or (iv) 丨' containing from 1% to % by weight of said extract, and from 1% to 5% by weight of a pharmaceutically acceptable carrier. The term "pharmaceutically acceptable carrier" means at least one compatible solid or liquid-filled pharmaceutically acceptable excipient that is conventionally known to those skilled in the art. Examples are lactose, glucose, sucrose, starches such as corn starch and horse starch, cellulose derivatives such as sodium carboxymethylcellulose, cellulose acetate, and microcrystalline cellulose (micr〇CIyStaiune) Cellulose) 〇27 200940081 The composition of the present invention is administered to a human (body weight of about 60 kg) at a suitable dose of 0.1 mg to 1 g. 'If each unit dose is labeled with a net weight of from 1 mg to 500 mg of active ingredient. And the unit dose is 丨 to 4 times. The dosage is combined with the administration method. It is appropriate to adjust the dosage according to the patient's age, weight and severity of the disease. The exact dose and route of administration are still basically adhered to. Judgment by a physician or veterinarian. The extract prepared according to the present invention exhibits anti-oxidation in a model of in vitro test (plus vz > 〇) The ability to liberate and scavenge free radicals, and demonstrates the efficacy of antioxidant stress in a bio-in vivo test (plus Wvo) model. According to another embodiment of the invention, adequate intake of mammals and avian individuals in need of treatment is sufficient An active dose composition which reduces or avoids its oxidative stress. The following are a few examples of compositions prepared in accordance with the present invention. The toxicity test carried out on the compositions of the present invention indicates that the experiment is large. Spmgue-Dawley rats The extract is administered orally at a dose of 3 gram per kilogram of body weight. The extract is not toxic. According to this, humans are orally administered with 3 grams of oil palm leaf extract per kilogram of body weight per day. The material was identified as suitable and safe. Example 1 Preparation of oil palm leaf extract Approximately 50 grams of dry oil palm leaf was mixed with 5 ml of water/alcohol mixture (volume ratio 3:7) and extracted at 60 degrees Celsius The temperature to 65 degrees is about 60 minutes. The liquid collected is then double-layered with a gauze buckle. This is also a transition to produce 28 200940081 raw 502 grams of the original extract. The resulting extract is then injected into the column for adsorption. Chromatography apparatus. The column (internal control 5.0 cm, length 4 〇 cm) is filled with Amberlite XAD16HP resin (manufactured by R0hm & Hass) to make the column volume about 78 〇 ml. The column is 4 to 5 times the column volume. The deionized water is washed. The raw extract obtained by the foregoing extraction step is injected into the column by a pump. The column is first dissolved in 1500 ml of deionized water to remove salts, sugars and other hydrophilic substances which are not desired to be retained. The column was then subjected to a 15 liter water/isopropyl alcohol mixture (3:7 by volume) at a steady flow rate of 25 ml per minute, an operating temperature of 60 degrees Celsius and a pressure of 0.5 to 1 bar. Dissolving to obtain a catechin gallate, fcruiic acid, and phenolic acid such as gallic acid and protocatechuic acid Purify the extraction liquid. The resulting extract liquid was further concentrated to 50 ml in a rotary evaporator, and the concentrate was placed in a vacuum oven at 60 ° C for drying for eight hours. The obtained 2.52 g of beige powder contains the following ingredients: catechin gallate component - 1.1% (measured by high performance liquid chromatography) fernic acid component - 1.5% (via High Performance Liquid Chromatography) Total phenolic acids -10.2% (measured by UV spectrometry) 29 200940081 Preparation of oil palm leaf extract 100 kg of fresh oil palm leaves are cut to a length of about 2 A small piece of centimeters is placed in the extraction tank. Add 1000 liters of water/isopropanol mixture (volume ratio of 3:7) and heat at 60 degrees Celsius for 8 hours. Filtered through a cartridge filter with ίο micropores to separate the original extract from the leaves. The filtered liquid is concentrated under reduced pressure of 7 〇〇 9 MPa (MPa) at 7 ° C to obtain about 2 liters of concentrated extract © (density of 1.10 to 1.20 per cubic centimeter) Gram ;). The resulting concentrated extract was then injected into an adsorption chromatography column which was a stainless steel column having a diameter of 15 cm and a length of 150 cm. The column is filled with a polyamide resin and has a particle size ranging from 3 Å to 6 Å. The column is then washed with 200 liters of deionized water and then at a steady flow rate of 1.5 liters per minute, an operating temperature of 20 to 3 degrees Celsius and a pressure of ❹ 0.5 to 1 bar, at 2 liters. The water/isopropanol mixture (volume ratio of 3:7) is dissolved to obtain a catechin gallate, feruiic acid, and phenacic acid such as phagoic acid. Purified extraction liquid of gallic acid and protocatechuic acid. The resulting extract liquid is then dried by a spray dryer. The inlet temperature of the spray dryer is set to about celsius 17 degrees to 180 degrees' and the outlet temperature is set to about Celsius to 105 degrees. The resulting 12.5 kilograms of beige powder contains the following ingredients: 30 200940081 catechin gallate ingredient-1 · 15% (measured by high performance liquid chromatography) fernlic acid component -1.6% (measured by high performance liquid chromatography) total phenolic acids -10.5% (via ultraviolet light) Spectrometer measurement) by quantitative and qualitative analysis Analysis of characteristics of the composition of the present invention. In the film liquid chromatography (Thin Layer Chromatography, TLC) and high performance liquid chromatography square method (High Performance Liquid

Chromatography，HPLC)定性分析本發明組合物含有兒茶素 沒食子酸(catechin gallate)、阿魏酸(ferulic acid)和沒食子酸 (gallic acid)成份之方法如下： 實例三 使用高效能液態層析法(HPLC)鑑定油棕葉萃取物中 所含之兒茶素沒食子酸(catechin gallatej 〇 將1毫克的兒茶素沒食子酸(catechin gallate)溶於1毫升 之濃度為0.1%的磷酸中以製備兒茶素沒食子酸的標準指示 溶液。同時’將200毫克的實例一中所得之本發明萃取物 溶於10毫升的酒精中以製備待測定溶液。 分別將上述兩溶液注入高效能液態層析法系統 (HPLC) ’而其實驗材料與參數為： ♦設備：Perkin Elmer液態層析(機型序號為2〇〇 LC); •管柱：Sinochrom ODS-BP column(250 公釐乘 4.6 公 31 200940081 釐之内徑，顆粒大小為5微米）； 鲁移動相：體積百分濃度2%的乙酸和乙睛之混合液； *於50分鐘内以線性梯度使用不同濃度之溶劑混合 液自92%經8%再提高至31〇/〇 ; •流速：每分鐘1.0毫升；以及， *偵測：波長280奈米之紫外光。 由標準指示溶液和待測定溶液之層析圖譜顯示，於流 滯時間28分鐘時呈現一個符合兒茶素沒食子酸(catechin gallate)的主要波峰。存在該波峰即確認於本發明組合物中 含有兒茶素沒食子酸(catechingaUate)的成份(請參第1圖）。 實例四 使用薄膜液態層析法(TLC)鏗定油棕葉萃取物中所含 之阿魏酸(ferulic acid)。 將實例一所得之油棕葉萃取物粉末溶於高效能液態層 析法(HPLC)等級之曱醇’接著以每分鐘4〇〇〇轉的速度離心 15分鐘’再提取上澄清液以製備為待測定液；使用曱醇/水 混合液(比例為7 : 1)作為展開劑，將待測定液和已知含量之 阿魏酸(feruhc acid)指示標準液點於預塗佈矽膠6〇之薄膜液 態層析法薄層(廠牌：E-Merck> ; 風乾該薄層後，再以波長254奈米的紫外光觀察。待 測定液和指示標準液皆可觀察到符合阿魏酸(femlic acid)的 淡紫色指示區域(請參第2圖）。 32 200940081 實例五 使用高效能液態層析法(HPLC)鑑定油標葉萃取物中 所含之沒食子酸(gallic acid)。 將10毫克的沒食子酸(gallic acid)溶於10毫升的甲醇中 以製備標準指示溶液；同時，將200毫克之實例一所得之 油棕葉萃取物溶於10毫升的甲醇以製備待測定溶液。 分別將上述兩溶液注入高效能液態層析法系統 (HPLC)，而其實驗材料與參數為：Chromatography, HPLC) Qualitative analysis of the composition of the present invention containing catechin gallate, ferulic acid and gallic acid as follows: Example 3 uses a high performance liquid Chromatography (HPLC) to identify catechin gallate contained in oil palm leaf extract (catechin gallatej 〇 1 mg of catechin gallate dissolved in 1 ml of 0.1 concentration In the % phosphoric acid, a standard indicating solution for preparing catechin gallic acid was used. At the same time, 200 mg of the extract of the present invention obtained in Example 1 was dissolved in 10 ml of alcohol to prepare a solution to be determined. The solution is injected into a high performance liquid chromatography system (HPLC)' and its experimental materials and parameters are: ♦ Equipment: Perkin Elmer liquid chromatography (model number is 2〇〇LC); • Column: Sinochrom ODS-BP column ( 250 mm by 4.6 mm 31 200940081 PCT inner diameter, particle size 5 μm); Lu mobile phase: 2% by volume of acetic acid and acetonitrile mixture; *Use different concentrations in a linear gradient within 50 minutes Solvent mixture from 92% 8% is further increased to 31 〇 / 〇; • Flow rate: 1.0 ml per minute; and, * Detection: ultraviolet light with a wavelength of 280 nm. Chromatogram of the standard indicating solution and the solution to be measured, showing the lag time At 28 minutes, a major peak corresponding to catechin gallate is present. The presence of this peak confirms the inclusion of catechina Uate in the composition of the present invention (please refer to paragraph 1). Fig. 4 Example 4 The membrane oil liquid chromatography (TLC) was used to determine the ferulic acid contained in the oil palm leaf extract. The oil palm leaf extract powder obtained in Example 1 was dissolved in a high performance liquid layer. Analytical (HPLC) grade sterol' followed by centrifugation at 4 rpm for 15 minutes' re-extraction of the supernatant to prepare the solution to be assayed; use a sterol/water mixture (ratio of 7:1) As a developing agent, the liquid to be measured and a known amount of feruhc acid indicating standard solution are placed on a thin film liquid chromatography thin layer of pre-coated silicone 6 (label: E-Merck>; air-dried After the thin layer, it was observed with ultraviolet light having a wavelength of 254 nm. A lavender indicating area conforming to femlic acid was observed in the indicated standard solution (see Figure 2). 32 200940081 Example 5 uses high performance liquid chromatography (HPLC) to identify oily leaf extracts. Gallic acid. 10 mg of gallic acid was dissolved in 10 ml of methanol to prepare a standard indicating solution; at the same time, 200 mg of the oil palm leaf extract obtained in Example 1 was dissolved in 10 ml of methanol to prepare a sample to be determined. Solution. The above two solutions were separately injected into a high performance liquid chromatography system (HPLC), and the experimental materials and parameters were:

❾ 鲁設備：Perkin Elmer液態層析(機型序號為2〇〇 lc); •管柱：Hypersil BDS碳18管柱(250公釐乘4.6公釐 之内徑，顆粒大小為5微米）； 翁移動相：甲醇、水和磷酸之混合液(比例為2〇 : 79 9 : 0.1); •流速：每分鐘1.0毫升；以及， 鲁偵測：波長270奈米之紫外光。 由標準指示溶液和待測定溶液之層析圖譜顯示，於流 滯時間6.6分鐘時呈現一個符合沒食子酸(gamc add)的主要 波峰。該波峰確認於本發明中存在有沒食子酸(gallic acid) 的成份(請參第3圖）。 以南效能液態層析法(High Performance Liquid Chromatography，HPLC)定量分析本發明組合物含有兒茶 素沒食子酸(catechin gallate)、阿魏酸(ferulic acid)和沒食子 酸(gallic acid)成份之方法如下： 33 200940081 實例六 使用高效能液態層析法(HPLC)定量油棕葉萃取物中 所含之兒茶素沒食子酸(catechin gallate) 〇 選用高效能液態層析法(HPL C)以測量實例一所得之油 棕葉萃取物中兒茶素沒食子酸(catechin gallate)的含量。 將1毫克的兒茶素沒食子酸(catechingallate)溶於1毫升 之濃度為0.1%的磷酸中以製備標準指示溶液。同時，將200 毫克的實例一中所得之本發明萃取物溶於10毫升的酒精中 以製備待測定溶液。 分別將上述兩溶液注入高效能液態層析法系統 (HPLC)，而其實驗材料與參數為： 鲁設備：Perkin Elmer液態層析(機型序號為200 LC); * 管柱：Sinochrom ODS-BP column(250 公釐乘 4.6 公 釐之内徑，顆粒大小為5微米）； 參移動相：體積百分濃度2%的乙酸和乙睛之混合液； *於50分鐘内以線性梯度使用不同濃度之溶劑混合 液自92%至8% ; 春流速：每分鐘1.0毫升； 鲁偵測：波長280奈米之紫外光；以及， 鲁注入體積：20微升。 判讀高效能液態層析法系統(HPLC)之實驗數據於流滯 時間28分鐘時’得到一個屬於兒茶素沒食子酸(catechin gallate)的峰面積(請參閱第4圖）。 藉由與標準指不溶液所含之兒茶素沒食子酸(catechin 34 200940081 gallate)相比較’以判讀待測定溶液中兒茶素沒食子酸 (catechin gallate)的含量。利用以下公式計算待測定溶液中兒 命素;又艮子酉曼(catechin gallate)的含量： 1000Crt/Wrs 其中： C代表由操作標準曲線curve)計算所 得之兒茶素沒食子酸(catechingallate)濃度(毫克/毫升）。 W代表用以製備待測定溶液之樣品重量(毫克）。 €> rt代表由待測定溶液所得之兒茶素沒食子酸(catechin gallate)峰面積。 rs代表由仏準指不溶液所得之兒茶素沒食子酸(catechin gallate)峰面積。 兒茶素沒食子酸(catechin gallate)之含量-1.1 %(經高效 能液態層析法測量） 高效能液態層析法(HPLC)顯示實例一所得之組合物中 之兒茶素沒食子酸(catechin gallate)的含量為1.1%。 實例七 使用高效能液態層析法(HPLC)定量油棕葉萃取物中 所含之阿魏酸(ferulic acid)。 選用高效能液態層析法(HPLC)以測量實例一所得之油 棕葉萃取物中阿魏酸(ferulic acid)的含量。 將阿魏酸(fernlic acid)溶於濃度為70%的酒精中以製備 四個已知濃度為0.15毫克/毫升、0.20毫克/毫升、〇 25毫克 35 200940081 /毫升和0.5毫克/毫升的阿魏酸(feruiic acid)的標準指示溶 液； 將10毫克實例一中所得之本發明萃取物溶於10毫升 的70%酒精中以製備待測定溶液； 分別將上述兩溶液注入高效能液態層析法系統 (HPLC)，而其實驗材料與參數為： •設備：Perkin Elmer液態層析(機型序號為200 LC); •管柱：Hypersil BDS碳18管柱(250公釐乘4.6公釐 Ο 之内徑，顆粒大小為5微米）； •移動相：曱醇和0.1%填酸的混合液(3〇 : 70); 鲁流速：每分鐘1.0毫升； #偵測：波長325奈米之紫外光；以及， ♦注入體積：20微升。 判讀高效能液態層析法系統(HPLC)之實驗數據於流滯 時間28·8分鐘時，得到一個屬於阿魏酸(fernlic acid)的峰面 ❹ 積(請參閱第5圖）。 藉由與標準指示溶液所含之阿魏酸(ferulic acid)相比 較’以判讀待測定溶液中阿魏酸(ferulic acid)的含量。利用 以下公式汁算待測定溶液中阿魏酸(fernlic acid)的含量： l〇〇〇Crt/Wrs 其中： c代表由實驗中標準指示溶液所得之操作標準曲線 Cwofking standard curve)計算所得之阿魏酸(fernlic acid)的濃 度(毫克/亳升)。 36 200940081 w代表用以製備待測定溶液之樣品重量(毫克）。 rt代表由待測定溶液所得之阿魏酸(feruiic扣⑷峰面積。 rs代表由標準指示溶液所得之阿魏酸(feruiic此吨峰面 積。 阿魏酸(fernlic acid)之含量-1.5%(經高效能液態層析法 測量） 高效能液態層析法(HPLC)顯示實例一所得之組合物中 之阿魏酸(ferulic acid)的含量為1.5%。 〇 實例八 紫外光譜定量油標葉萃取物中所含之所有紛酸 (phenolic acids) ° 選用％外光光譜儀以測量實例一所得之油掠葉萃取物 中紛酸(phenolic acids)的總含量。 將毫克的原兒茶酸(protocatechuic acid)溶於100毫 升的HPLC等級之曱醇以製備標準指示溶液；再用hplc 等級之甲醇將10毫升之所得溶液以1比9的比例稀釋。 不同罝之標準指示溶液與1毫升的曱醇(做為空白溶液) 分別經滴量管置入容積為25毫升之燒瓶。於每一個燒瓶中 加入5毫升之絕對酒精(absolute ethanol)、2亳升之3%的十 二烷基硫酸鈉(sodium dodecyl sulfate)溶液和1.〇亳升之顯色 試劑(chromogenic reagent，0.9%的鐵氰化鉀 ferricyanide)水溶液：0.9%的氯化鐵(ferric chloride)水溶液 (0.9:1))。 37 200940081 將標準指示溶液和空白溶液放於暗室中5分鐘。每一 燒瓶中之溶液以0.1莫耳濃度之鹽酸水溶液調配至一定體 積並混合均勻，再放置於暗室中2〇分鐘。以空白溶液為基 準’測量標準指示溶液於波長679奈米光源的吸光值。以 標準指不魏之濃度為X軸’域光值為γ軸讀製一標 準計算曲線。 ❹ 此量測係根據紫外光光譜法，將1G毫克之組合物溶於 10毫升的7〇%酒精中；再以滴量管將〇 〇5毫升之溶液放入 燒瓶，待測定溶液係以上述之相同方法製備。 量測油棕葉萃取物中所有酚酸⑽咖此此㈣於波長 679奈米光源的吸光值(請參閱第6圖）。 根據“t算曲線’計算標輔示溶液帽崎hen〇Uc acids)之總濃度。 利用下述公式計算待測定溶液中紛酸⑽哪此&⑽之 總濃度並以百分比(％)呈現：❾ Lu equipment: Perkin Elmer liquid chromatography (model number 2〇〇lc); • Column: Hypersil BDS carbon 18 column (250 mm by 4.6 mm inner diameter, particle size 5 microns); Mobile phase: a mixture of methanol, water and phosphoric acid (ratio 2: 79 9 : 0.1); • flow rate: 1.0 ml per minute; and, Lu detection: ultraviolet light with a wavelength of 270 nm. A chromatogram of the standard indicator solution and the solution to be determined showed a major peak corresponding to gallic acid at a flow time of 6.6 minutes. This peak was confirmed to have a component of gallic acid in the present invention (see Fig. 3). Quantitative analysis of the composition of the present invention containing catechin gallate, ferulic acid and gallic acid by High Performance Liquid Chromatography (HPLC) The ingredients are as follows: 33 200940081 Example 6 Quantitative liquid chromatography (HPLC) for the determination of catechin gallate in oil palm leaf extract 〇 High-performance liquid chromatography (HPL) C) The content of catechin gallate in the oil palm leaf extract obtained by the measurement example 1. A standard indicator solution was prepared by dissolving 1 mg of catechin gallate in 1 ml of 0.1% phosphoric acid. Meanwhile, 200 mg of the extract of the present invention obtained in Example 1 was dissolved in 10 ml of alcohol to prepare a solution to be measured. The above two solutions were respectively injected into a high performance liquid chromatography system (HPLC), and the experimental materials and parameters were: Lu equipment: Perkin Elmer liquid chromatography (model number is 200 LC); * Column: Sinochrom ODS-BP Column (250 mm by 4.6 mm inner diameter, particle size 5 μm); mobile phase: 2% by volume of acetic acid and acetonitrile mixture; * use different concentrations in a linear gradient over 50 minutes Solvent mixture from 92% to 8%; Spring flow rate: 1.0 ml per minute; Lu detection: UV light with a wavelength of 280 nm; and, Lu injection volume: 20 μL. The experimental data of the high performance liquid chromatography system (HPLC) was judged to give a peak area belonging to catechin gallate at a lag time of 28 minutes (see Fig. 4). The content of catechin gallate in the solution to be assayed is determined by comparison with catechin 34 gallate gallate (catechin 34 200940081 gallate) contained in the standard solution. Calculate the amount of catechin gallate in the solution to be determined by the following formula; and the content of catechin gallate: 1000Crt/Wrs where: C represents the catechinal gallate calculated from the operating standard curve curve) Concentration (mg/ml). W represents the weight (mg) of the sample used to prepare the solution to be tested. €> rt represents the catechin gallate peak area obtained from the solution to be tested. Rs represents the area of the catechin gallate peak obtained from the non-solution of 仏. The content of catechin gallate - 1.1% (measured by high performance liquid chromatography) High performance liquid chromatography (HPLC) shows the catechins in the composition obtained in Example 1. The content of catechin gallate was 1.1%. Example 7 The ferulic acid contained in the oil palm leaf extract was quantified using high performance liquid chromatography (HPLC). High performance liquid chromatography (HPLC) was used to measure the content of ferulic acid in the oil palm leaf extract obtained in Example 1. Ferulic acid was dissolved in 70% alcohol to prepare four known concentrations of 0.15 mg/ml, 0.20 mg/ml, 〇25 mg 35 200940081/ml and 0.5 mg/ml. a standard indicator solution of feruiic acid; 10 mg of the extract of the present invention obtained in Example 1 is dissolved in 10 ml of 70% alcohol to prepare a solution to be determined; respectively, the above two solutions are injected into a high performance liquid chromatography system (HPLC), and the experimental materials and parameters are: • Equipment: Perkin Elmer liquid chromatography (model number is 200 LC); • Column: Hypersil BDS carbon 18 column (250 mm by 4.6 mm Ο) Diameter, particle size 5 microns); • Mobile phase: a mixture of decyl alcohol and 0.1% acid (3〇: 70); Lu flow rate: 1.0 ml per minute; #Detection: ultraviolet light with a wavelength of 325 nm; ♦ Injection volume: 20 microliters. The experimental data of the High Performance Liquid Chromatography System (HPLC) was obtained at a lag time of 28.8 minutes to obtain a peak surface enthalpy of fernic acid (see Figure 5). The content of ferulic acid in the solution to be assayed is determined by comparing with the ferulic acid contained in the standard indicating solution. Calculate the content of fernlic acid in the solution to be determined by the following formula: l〇〇〇Crt/Wrs where: c represents the calculated Wawofking standard curve obtained from the standard indicating solution in the experiment. The concentration of fernlic acid (mg/μl). 36 200940081 w represents the weight (mg) of the sample used to prepare the solution to be determined. Rt represents the ferulic acid (ferreic acid (4) peak area obtained from the solution to be determined. rs represents the ferulic acid obtained from the standard indicating solution (feruiic this tonnage peak area. ferulic acid (fernlic acid) content -1.5% (via High performance liquid chromatography measurement) High performance liquid chromatography (HPLC) showed that the content of ferulic acid in the composition obtained in Example 1 was 1.5%. 〇 Example 8 UV spectroscopy quantification of oil leaf extract All phenolic acids contained °%% external light spectrometer was used to measure the total content of phenolic acids in the oil-swept leaf extract obtained in Example 1. Dissolving milligrams of protocatechuic acid 100 ml of HPLC grade sterol was prepared to prepare a standard indicator solution; 10 ml of the resulting solution was diluted with hplc grade methanol in a ratio of 1 to 9. Different oxime standards indicated solution and 1 ml of sterol (as Blank solution) Place a 25 ml flask through a dropper tube. Add 5 ml of absolute ethanol and 2 liters of sodium dodecyl sulfate to each flask. ) solution and 1. An aqueous solution of chromogenic reagent (0.9% potassium ferricyanide): 0.9% aqueous ferric chloride solution (0.9:1). 37 200940081 Place the standard indicator solution and blank solution in 5 minutes in the dark room. The solution in each flask was prepared to a certain volume with a 0.1 molar aqueous solution of hydrochloric acid and mixed well, and then placed in a dark room for 2 minutes. Based on the blank solution, the measurement standard indicates the solution at a wavelength of 679 奈. The absorbance value of the rice light source. The standard calculation curve is based on the standard deviation of the X-axis 'field light value as the γ axis. ❹ This measurement is based on the ultraviolet light spectroscopy method, the 1G milligram of the composition is dissolved in 10 5% of the alcohol in 7〇%; then put 5 ml of the solution into the flask with a drop tube, and the solution to be determined is prepared in the same manner as above. Measure all the phenolic acids in the oil palm leaf extract (10) (4) The absorbance of the light source at a wavelength of 679 nm (see Figure 6). Calculate the total concentration of the solution 帽 〇 〇 Uc acids according to the “t-calculus curve.” Calculate the solution to be determined using the following formula. Acid (10) which & (10) The total concentration is expressed as a percentage (%):

50,000 C/W 其中： C代表由實驗帽轉轉液所得之操作標準曲線 (working standard 濃度(毫克/毫升）。 CUrve)計算所得之酚酸(phenolic acid)之總 W代表用崎備待觀溶液之樣品重量(毫克）。 紫外光光麵示，實例—所得德合物巾紐(phenolic acid)之總濃度為1〇 2%。 38 200940081 實例九 經生體内(/#f v/w)模型和生體外(知模型以測定本 發明组合物之抗氧〇 本發明組合物之抗氧化活性以下述生體内(加咖〇)模型 和生體外(Z>7 W/W)模型測定： 本發明組合物清除二苯聯苦基自由基贝卩^自由基） 之活性。 藉由二苯聯苦基(DPPH)於波長517奈米之色度測量以 測疋於實例一所得之本發明組合物清除二苯聯苦基自由基 (DPPH自由基)之活，陡。 計算二苯聯苦基(DPPH)從紫色轉變為黃色所造成吸光 值的下降以評估活性。 將10毫克實例一中所得之樣品粉末溶於5毫升的絕對 酒精中以製備樣品溶液，且製備溶於酒精而濃度為〇.2毫莫 耳/升的二苯聯苦基(DPPH)溶液。將1毫升的二苯聯苦基 (DPPH)溶液加入4毫升的樣品溶液。接著將該樣品溶液放 置於暗室中30分鐘。於波長517奈米測量樣品溶液之吸光 值。較低的吸光值顯示較強的自由基清除活性。用丁基經 基甲氧苯(1>1吵如6(111>^1*(汉111〇8〇^，311^)作為對照。測量之 樣品濃度越高，觀察到的自由基清除能力也就越強。實驗 結果顯示，本發明組合物展現了較丁基經基甲氧苯 (butylatedhydroxinasole，BHA)更強的抗氧化活性。 39 濃度(毫克/毫升） 二苯聯苦基自由基(DPPH自由基)清除百 丁基羥基甲氧苯(BHA) μ實例一所得之油棕葉萃取物 0.125 58.15 92.52 0.25 67.79 95.78 0.5 79.76 97.18 1 86.84 96.84 2 94.12 94.34 表格一：比較油棕葉萃取物和丁基羥基曱氧苯(BHA)對於二苯聯苦基自 由基(DPPH自由基)的清除百分比(％)。 200940081 實例十 本發明組合物之還原能力 藉鐵氰化鉀(potassium ferricyanide)還原法測定實例一 所得之本發明組合物的還原能力。將1〇毫克實例一中所得 之樣品粉末溶於1〇毫升的絕對酒精中以製備樣品溶液。將 1毫升的樣品溶液溶於1亳升的蒸餾水中，再混合2 5毫升 而濃度為0.2莫耳/升的磷酸鹽緩衝液，以及2 5毫升而濃度 為1彳的鐵氰化卸(potassium ferricyanide)水溶液。此混合液 接著放置於攝氏50度20分鐘。再將2.5毫升而濃度為1〇〇/0 的二氯乙酸(trichloroacetic acid)水溶液加入每一個樣品溶液 中。樣品溶液以3000轉的速度離心1〇分鐘。將2 5毫升的 上澄清液混合2.5毫升的蒸餾水和〇 5毫升而濃度為〇1%的 氯化鐵(ferric chloride)水溶液。該溶液(鐵氰化鉀溶液)的黃 色經組合物之還原能力作用而變為淡黃色。組合物中所含 的還原劑(抗氧化劑)使三價鐵離子(氰化鐵複合物)還原為二 價鐵形式。二價鐵錯合物藉其形成普魯士藍可於波長7〇〇 200940081 奈求被測量(測量於波長700奈米的吸光值)。吸光值的增加 意味者還原能力的增加’並使用丁基經基甲氧苯作為 對照。實驗結果顯示，組合物展現了與丁基經基甲氧苯 (BHA)相當的還原能力。 濃度(毫克/毫升） 於波長700奈米之吸光值 丁基羥基曱氧苯(BHA) 實例一所得之油榇鼇笨取物 1 0.8897 0.2296 0.5 0.7322 0.1603 0.25 0.5777 0.1177 0.0625 0.2769 0.0015 0.125 0.4054 0.0115 表格二：油棕葉萃取物和丁基羥基曱氧苯(BHA)的還原能力。 實例十一 活體試驗脂質過氧化現象藉油棕葉萃取物之還原作用 藉脂質過氧化測定法(malondialdehyde test)測定油棕葉 萃取物抑制脂質過氧化現象之特性，以論證油棕葉萃取物 之抗氧化壓力活性。脂質氧化並形成丙二醛 (malondialdehyde ’ MDA)是自由基於生物體内最具破壞力的 影響之一。測量具有脂質過氧化現象之動物體内血清中硫 代巴比妥酸反應物質（thiobarbituric acid reactive substances，TBARS)的含量，即可評估其脂質過氧化現象的 程度。丙二搭(malondialdehyde，MDA)與硫代巴比妥酸反應 物質(thiobarbituric acid reactive substances，TBARS)反應會 生成具有顏色而能以色度法測量的物質。 藉由腹腔注射(intraperitoneal injection)四氣化碳(carbon \200940081 每公斤體重給予單劑 每公斤體重給予單劑 ,,上 之四氣化破 根據下列表格三所示，經誘發脂質過氧化現象之大鼠 (正向對照組)相較於對照組之大鼠血清内含有較高濃度的 丙二醛(malondialdehyde，MDA)。經施與實例一所得之組合 物的大鼠之血清中的丙二酸{malondialdehyde，MDA)有降低 的現象，顯示油棕葉萃取物具有抑制脂質過氧化現象以及 抗氧化壓力之活性。 組別 大鼠編號 (共6隻） 血清中丙二搭(malondialdehyde， _ MDA)之平均道唐(夺节不/年并、 對照組 6 1.913 正向對照組 6 ... 2.851 實驗組 6 1.947 Ο50,000 C/W where: C represents the operating standard curve (working standard concentration (mg/ml) obtained from the experimental cap transfer solution. CUrve) The total W of the calculated phenolic acid represents the use of the solution Sample weight (mg). The ultraviolet light surface shows that the total concentration of the obtained phenolic acid is 1 〇 2%. 38 200940081 Example nine-vivo (/#fv/w) model and in vitro (knowledge model to determine the antioxidant activity of the composition of the invention) The antioxidant activity of the composition of the invention is in the following organism (plus curry) Model and in vitro (Z> 7 W/W) model determination: The composition of the present invention scavenges the activity of diphenyl hydrazino radicals. The composition of the present invention obtained by the example 1 obtained by the diphenyl hydrazine group (DPPH) at a wavelength of 517 nm was used to remove the diphenyl hydrazino radical (DPPH radical), which was steep. The decrease in absorbance caused by the conversion of diphenyl hydrazine (DPPH) from purple to yellow was calculated to evaluate the activity. 10 mg of the sample powder obtained in Example 1 was dissolved in 5 ml of absolute alcohol to prepare a sample solution, and a diphenyl hydrazine (DPPH) solution dissolved in alcohol at a concentration of 毫2 2 mol/liter was prepared. 1 ml of a diphenyl hydrazine (DPPH) solution was added to 4 ml of the sample solution. The sample solution was then placed in a dark room for 30 minutes. The absorbance of the sample solution was measured at a wavelength of 517 nm. Lower absorbance values show stronger free radical scavenging activity. Using butyl methoxybenzophenone (1 > 1 noisy as 6 (111 > ^1 * (Han 111 〇 8 〇 ^, 311 ^) as a control. The higher the sample concentration measured, the observed free radical scavenging ability The stronger the results, the experimental results show that the composition of the present invention exhibits stronger antioxidant activity than butylated hydroxinasole (BHA). 39 Concentration (mg/ml) Diphenyl bonded bit radical (DPPH) Free Radical) Removal of Penta Butyl Hydroxymethoxybenzene (BHA) μ Oil Palm Leaf Extract 0.125 58.15 92.52 0.25 67.79 95.78 0.5 79.76 97.18 1 86.84 96.84 2 94.12 94.34 Table 1: Comparison of Oil Palm Leaf Extract and Ding Percentage (%) of removal of diphenyl hydrazine radical (DPPH radical) by hydroxy oxybenzene (BHA). 200940081 Example 10 Reduction ability of the composition of the present invention by potassium ferricyanide reduction method The reducing ability of the composition of the present invention obtained in Example 1. The sample powder obtained in Example 1 of Example 1 was dissolved in 1 mL of absolute alcohol to prepare a sample solution. 1 ml of the sample solution was dissolved in 1 liter of distilled water. Medium, remix 2 5 ml of phosphate buffer at a concentration of 0.2 mol/l and 25 ml of a ferric cyanide aqueous ferricyanide solution at a concentration of 1 Torr. The mixture was then placed at 50 ° C for 20 minutes. 2.5 ml of an aqueous solution of trichloroacetic acid at a concentration of 1 〇〇 / 0 was added to each sample solution. The sample solution was centrifuged at 3000 rpm for 1 Torr. 25 ml of the supernatant was mixed with 2.5 ml. Distilled water and hydrazine 5 ml of a ferric chloride aqueous solution having a concentration of 〇1%. The yellow color of the solution (potassium ferricyanide solution) was changed to a pale yellow color by the reducing ability of the composition. The reducing agent (antioxidant) reduces the ferric ion (iron cyanide complex) to the form of divalent iron. The divalent iron complex can be measured by the Prussian blue at wavelength 7〇〇200940081 (measurement) The absorbance at a wavelength of 700 nm). The increase in absorbance means an increase in reducing power' and the use of butyl methoxybenzophenone as a control. The experimental results show that the composition exhibits butyl methoxy benzene ( BHA) considerable reduction Capacity. Concentration (mg/ml) Absorbance of butyl hydroxy oxybenzene (BHA) at a wavelength of 700 nm. Example 1 obtained from oil mites 1 0.8897 0.2296 0.5 0.7322 0.1603 0.25 0.5777 0.1177 0.0625 0.2769 0.0015 0.125 0.4054 0.0115 Table 2: Reduction ability of oil palm leaf extract and butylhydroxy oxybenzene (BHA). Example 11 In vivo test lipid peroxidation by oil palm leaf extract reduction by lipid peroxidation assay (malondialdehyde test) determination of oil palm leaf extract inhibition of lipid peroxidation characteristics to demonstrate oil palm leaf extract Antioxidant pressure activity. Lipid oxidation and formation of malondialdehyde (MDA) is one of the most destructive effects in the body. By measuring the content of thiobarbituric acid reactive substances (TBARS) in the serum of animals with lipid peroxidation, the degree of lipid peroxidation can be evaluated. The reaction of malondialdehyde (MDA) with thiobarbituric acid reactive substances (TBARS) produces a substance that is color-measured by the colorimetric method. By intraperitoneal injection of four gasified carbon (carbon \200940081 per kg body weight given a single dose per kilogram of body weight given a single dose, the fourth gasification break according to the following table three, induced by lipid peroxidation Rats (forward control group) contained higher concentrations of malondialdehyde (MDA) in the serum of the rats than the control group. The serum of the rats in the serum of the composition obtained by the application of Example 1 The acid {malondialdehyde (MDA) has a reduced phenomenon, indicating that the oil palm leaf extract has an activity of inhibiting lipid peroxidation and anti-oxidation stress. Group rats numbered (total of 6) Serum in the mean of malondialdehyde (_MDA). The rats were killed (years were not/year, and the control group was 6.913. The positive control group was 6 ... 2.851 experimental group 6 1.947 Ο

tetrarchloride)以誘發脂質過氧化現象 組別 大鼠編號 施與 (共6隻） (第1〜5天） 對照組 6 正向對照組 6 純水 實驗組 6 每公斤體重給予1.1克的 實例一所得之組合物 --------- 給予四氣化；^Tetrarchloride) was induced by the number of rats induced by lipid peroxidation (6 in total) (1st to 5th day). Control group 6 Positive control group 6 Pure water experimental group 6 1.1 g per kg body weight of Example 1 Composition--------- give four gasification; ^

實例十二 油棕葉萃取物之安全性Example 12 Safety of oil palm leaf extract

測定最大耐受量(maximiun tolerated dose，MTDJ 動物實驗已證實食用油標葉萃取物之安全性。於實驗 大鼠(Spmgue-Dawley rats)施與實例一所得之油棕葉萃取物 的毒物學測試顯示’即使於每公斤體重口服劑量2克之油 棕葉萃取物，該組合物仍為安全的(完全沒有任何死亡的癥 狀）。 42 200940081 最大耐受置(maximum tolerated dose，MTD)之測定如下 所述： 每三隻體重150克至180克的大鼠為一組，分組施與 每公斤體重2克、5克、7克、9克、11克、13克、16克、 19克、25克、30克和35克之組合物。組合物先溶於純水 中再以口服劑的方式施與每一動物。對照組中，相同隻數 的大鼠經口服施與純水。 動物於施與30分鐘之後分別接受觀察，於頭24小時 〇 内定時地觀察’其中頭四個小時特別觀察，爾後，每一天 進行觀察達總觀察天數14天。觀察項目包括整體行為上的 改變、基本行動能力、扭動、抽搐、對於捏夾尾巴的反應、 唱咬能力、起苑疼現象、瞳孔大小、***量、進食行為、 死亡癥狀等。記錄體重的改變也一併紀錄。主要的觀察項 目為死亡癥狀。 母公斤體重施與30克油棕葉萃取物的組別沒有任何死 0 亡和中毒反應，因此最大耐受量(maximum tolerated dose， MTD)為每公斤體重施與30克。 人類的日常一天之建議劑量為每公斤體重約0.03克的 油棕葉萃取物。 比較人類的日常一天之建議劑量與大鼠的最大耐受量 (maximum tolerated dose，MTD) ’ 大鼠的最大财受量 (maximum tolerated dose，MTD)之倍數為： =大鼠的最大耐受量(公克/每公斤體重)/人類每曰劑量 (公克/每公斤體重） 43 200940081 =30.0/0.03 =1000 倍 結論·大鼠對於實例一所得之油棕葉萃取物的最大耐 受量為每公崎3〇克，相當於人類σ服建議継的誦 倍。顯不本發明組合物的致死毒性極低，且非常安全於人 類口服使用。 實例十三The maximum tolerated dose (maximun tolerated dose) was confirmed in the MTDJ animal experiment. The toxicological test of the oil palm leaf extract obtained in Example 1 was applied to the experimental rats (Spmgue-Dawley rats). 'Even with an oral dose of 2 grams of oil palm leaf extract per kilogram of body weight, the composition is safe (no symptoms of any death at all). 42 200940081 The maximum tolerated dose (MTD) is determined as follows : Each group of rats weighing 150 grams to 180 grams is administered in groups of 2 grams, 5 grams, 7 grams, 9 grams, 11 grams, 13 grams, 16 grams, 19 grams, 25 grams per kilogram of body weight. 30 g and 35 g of the composition. The composition was first dissolved in pure water and then administered to each animal as an oral agent. In the control group, the same number of rats were orally administered with pure water. After the minute, they were observed separately. During the first 24 hours, they observed regularly for the first four hours of observation. After that, they observed each day for 14 days. The observation items included changes in overall behavior, basic operational ability, Movement, convulsions, reaction to pinch tail, sing ability, body pain, pupil size, excretion, eating behavior, death symptoms, etc. Record changes in weight are also recorded. The main observation item is death symptoms. The group weighing 30 grams of oil palm leaf extract does not have any death or poisoning reaction, so the maximum tolerated dose (MTD) is 30 grams per kilogram of body weight. The recommended dosage is about 0.03 grams of oil palm leaf extract per kilogram of body weight. Compare the recommended daily dose of human to the maximum tolerated dose (MTD) of the rat 'maximum tolerated The multiple of dose, MTD) is: = maximum tolerated dose in rats (g / kg body weight) / human per dose (g / kg body weight) 43 200940081 = 30.0 / 0.03 = 1000 times conclusion · rat for examples The maximum tolerated amount of the obtained oil palm leaf extract is 3 gram per kiln, which is equivalent to 诵 times the recommended 継 of human σ. It is obvious that the composition of the present invention has extremely low lethal toxicity and is very safe. Class oral use. Examples of thirteen

製造軟明膝膠囊的方法Method for manufacturing soft knee capsule

下述成份經混合以形成同相之油性懸浮液。 軟明膠膠囊之配方：The following ingredients were mixed to form an in-phase oily suspension. Soft gelatin capsule formula:

實例—所得之油棕葉萃取粉末 (經標準化含有i.1%的兒茶素沒食子酸， 200.00毫克 功效成份 —由酯 囊中 址·»你^付 —-1^2_5·〇〇毫克 轨瓶 接者將所仵之油性懸 實例十四 製造藥錢:的方法 具有下述配方之藥錠依據下述描述製備。 嶋壓錠法(direct c〇mpre，製造該藥錠 份混合同相後’再_錠機壓型為圓形藥錠⑽毫克/錠)。 44 200940081 藥錄:配方： 成份 量/錠 功用 實例一所得之油棕葉萃取粉末 (經標準化含有1.1%的兒茶素沒食子酸， 1.5%的阿魏酸，以及10.2%的總酚酸） 350.00毫克 功效成份 澱粉 77.00毫克 稀釋劑 微晶纖維素 175.00毫克 稀釋劑 聚乙烯吡咯烷酮K30 21.00毫克 黏合劑 羧曱基澱粉 70.00毫克 破碎劑 硬脂酸鎮 7.00毫克 潤滑劑 Ο 實例十五 製造硬明勝膠囊的方法 下述配方之組成物經所屬技藝領域中具有通常知識者 所知之標準程序製備成硬膠囊。 下列成份經混合而形成一同相之混合粉末。 所得之混合物接著填充入一號尺寸的硬明膠膠囊。 硬明膠膠囊之配方： 成份 量/膠囊 功用 實例一所得之油棕葉萃取粉末 (經標準化含有1.1%的兒茶素沒食子酸， 1.5%的阿魏酸，以及10.2%的總酚酸） 200.00毫克 功效成份 澱粉 144.75毫克 稀釋劑 二氧化矽 3.50毫克 抗結劑 硬脂酸鎮 1.75毫克 潤滑劑 實例十六 口服懸浮液 含下列組成物之液態口服懸浮液依據下述製備： 45 200940081 瓶 本發明之油棕料轉雜著觀人色之玻璃 口服懸浮液之配方： 成份 實例一所得之油棕葉萃取粉末 (經標準化含有1.1%的兒茶素沒食子酸， 1.5%的阿魏酸，以及10.2%的總盼酸） 羧甲基纖維素鈉 羥苯甲酸甲酯 對經基苯甲酸丙酯 Γ/100毫升 〇.50 克 功用 功效成份 懸浮劑 Ο 草莓風味油 聚山梨醇酯80 適量純水 〇·〇9 克ΐΐ〇Τ 〇·1〇 克 0.10 克 100毫升 防腐劑 防腐劑 調味劑 濕潤劑 載體 【圖式簡單說明】 第1圖係測定油棕葉萃取物含兒茶素沒食子酸之高效 能液態層析圖，其中，第1Α圖代表兒茶素沒食子酸(catechin gallate)之標準指示溶液’第1B圖代表油棕葉萃取物； 第2圖係測定油棕葉萃取物含阿魏酸之薄膜液態層析 〇 圖； 第3圖係測定油棕葉萃取物含沒食子酸之高效能液態 層析圖，其中’第3A圖代表沒食子酸(gallicacid)之標準指 示溶液’第3B圖代表油棕葉萃取物； 第4圖係定量油棕葉萃取物中兒茶素沒食子酸含量之 高效能液態層析圖，其中，第4A圖代表兒茶素沒食子酸 (catechingallate)之標準指示溶液，第4B圖代表油棕葉萃取 物； 46 200940081 第5圖係定量油棕葉萃取物中阿魏酸含量之高效能液 態層析圖，其中，第5A圖代表阿魏酸(femlicacid)之標準指 示溶液，第5B圖代表油棕葉萃取物；以及， 第6圖係定量油棕葉萃取物中所有盼酸含量之紫外光 光譜圖。 【主要元件符號說明】 無Example - the obtained oil palm leaf extract powder (standardized to contain i.1% catechin gallate, 200.00 mg functional ingredient - from the base of the ester sac · you ^ pay -1^2_5·〇〇 mg The ore bottle holder will apply the oily suspension of the example. The method has the following formula: The tablet is prepared according to the following description. Direct c〇mpre, after the ingot is mixed in phase Re-ingot molding is a round ingot (10 mg/ingot). 44 200940081 Record: Formulation: Ingredient/Ingots Example 1 Oil palm leaf extract powder (standardized to contain 1.1% catechins. Acid, 1.5% ferulic acid, and 10.2% total phenolic acid) 350.00 mg functional ingredient starch 77.00 mg thinner microcrystalline cellulose 175.00 mg thinner polyvinylpyrrolidone K30 21.00 mg binder carboxymethyl starch 70.00 mg broken Agent Stearic Acid Town 7.00 mg Lubricant Ο Example 15 Method for Making Hard Mingsheng Capsules The compositions of the following formulations were prepared into hard capsules by standard procedures known to those skilled in the art. Combine to form a mixed powder of the same phase. The resulting mixture is then filled into a size hard gelatin capsule. Formulation of hard gelatin capsules: Ingredient amount / Capsule Application Example 1 Oil palm leaf extract powder (standardized to contain 1.1% Catechin gallic acid, 1.5% ferulic acid, and 10.2% total phenolic acid) 200.00 mg functional ingredient starch 144.75 mg thinner ceria 3.50 mg anti-caking agent stearic acid town 1.75 mg lubricant example ten Six Oral Suspensions The liquid oral suspensions containing the following compositions are prepared according to the following: 45 200940081 Bottles of the oil palm material of the present invention are mixed with a glass oral suspension of the human color: Ingredient Example 1 obtained oil palm leaf extract Powder (standardized to contain 1.1% catechin gallate, 1.5% ferulic acid, and 10.2% total acid) carboxymethyl cellulose sodium hydroxybenzoate propyl propyl benzoate /100ml 〇.50 grams of functional ingredient suspension Ο strawberry flavor oil polysorbate 80 amount of pure water 〇·〇9 gram 〇·1 gram 0.10 gram 100 ml preservative antiseptic Agent flavoring agent wetting agent carrier [simple description of the figure] Figure 1 is a high-performance liquid chromatogram of the oil palm leaf extract containing catechin gallate, wherein the first map represents catechins. The standard indication solution of acid (catechin gallate) represents the oil palm leaf extract in Figure 1B; the liquid chromatogram of the film containing ferulic acid in the oil palm leaf extract is determined in Figure 2; The extract contains a high-performance liquid chromatogram of gallic acid, where 'Grade 3A represents a standard indicator solution for gallic acid' Figure 3B represents oil palm leaf extract; Figure 4 is a quantitative oil palm High-performance liquid chromatogram of catechin gallate content in leaf extract, wherein Figure 4A represents the standard indicator solution of catechin gallate, and Figure 4B represents oil palm leaf extract. 46 200940081 Figure 5 is a high-performance liquid chromatogram of the ferulic acid content in the oil palm leaf extract, wherein Figure 5A represents the standard indicator solution of femlic acid and Figure 5B represents the oil palm leaf. Extract; and, Figure 6 is a quantitative oil palm leaf extract Ultraviolet spectrum of all acid content. [Main component symbol description] None

〇 47〇 47

Claims (1)

200940081 * 七、申請專利範圍： 1. 一種含油棕葉萃取物之組合物，其特徵在於，·所述萃取 物含有兒茶素沒食子酸、阿魏酸以及酚酸如沒食子酸和 原兒茶酸。 2. 如申請專利範圍第1項所述組合物，其中，上述油棕葉 採自非洲油棕和美洲油棕所構成之油棕屬植物。 3. 如申請專利範圍第1項或第2項所述組合物，其中，上 述兒茶素沒食子酸佔總重量之百分之〇1至百分之95。 〇 4.如申請專利範圍第1項或第2項所述組合物，其中，上 述阿魏酸佔總重量之百分之01至百分之95。 5. 如申睛專利範圍第1項或第2項所述組合物，其中，上 述紛酸是沒食子酸。 6. 如申請專利範圍第1項、第2項或第5項所述組合物， 其中，上述酚酸成份佔總重量之百分之〇丨至百分之 95 ° 7. -種製造油棕鮮取物的方法，含兒茶素沒食子酸、阿 〇 賊以及_如沒食子酸和縣茶酸，包含步驟： ⑻將乾燥或轉的油棕葉與水、賴、情、丙嗣、 乙酸乙醋、氣仿、異丙醇、或所述溶劑之混合劑， 或其他極性溶劑相混合，再於攝氏25度至95度之 /皿度範圍内加熱G.5小時至96小時，以萃取油標葉 中的植物液； (b) 過濾步驟(a)中萃取得之植物液； (c) 使步驟(b)巾所得之_液與吸_析基質接觸以 48 200940081 選擇性吸附特定成份，即，使兒茶素沒食子酸、阿 魏酸以及酚酸如沒食子酸和原兒茶酸保留；該吸附 基質為管柱吸附基質或其他吸附基質； (Φ使用水、酒精、曱醇、丙酮、乙酸乙酯、氯仿、異 丙醇、或所述溶劑之混合劑，或其他極性溶劑將步 驟(C)中所述成份自吸附管柱基質中溶離出來；以 及， 〇 (e)使时霧式錢H、真空烘箱、f通烘箱、微波供 箱或冷凍乾燥器乾燥並濃縮上述步驟(d)所得之^ 物液。 8. 如申睛專利範圍第7項所述方法，其中’根據上述方法 所得之含有兒茶素沒食子酸、阿魏酸以及酚酸如沒食子 酸和原兒茶酸之油棕葉萃取物。 9. 如申請專利範圍第7項所述方法，其中，上述萃取物來 自非洲油棕。 Ο 1〇.如申請專利範圍第7項所述方法，其中，上述溶劑包含 至少一選自水、曱醇、酒精、丙_!、乙酸乙酯、異丙醇、 氣仿和所述溶劑之混合液所組成之族群中至少一種。 11.如申請專利範圍第7項所述方法，其中，上述分離基質 包含一聚合層析管柱。 如申請專利範圍第7項所述方法，其中，上述分離基質 包含一合成聚合樹脂。 13.如申請專利範圍第7項所述方法，其中，上述聚合樹脂 為聚苯乙烯。 49 200940081 14::=利範圍第7項所述方法，其中，上述乾燥的步 驟包含噴霧式乾燥。 15 圍第7項所述油方法，其中，上述溶離劑 3 /一種選自水、甲醇、酒精、丙酮、乙酸乙酯、 、=醇、H仿、或所述溶劑之混合劑所減之族群中。 Ο 物，Γ專利㈣第1項至第6項任—項所述治療用組合 H/、中’上述組合物之形式為茶飲、㈣、膜衣銳、 Λ 嚼錠、膠囊，軟膠囊、顆_、膜衣顆粒劑、 政劑膜衣散劑、藥液、糖漿、乳液或懸浮劑。 .種4藥用組合物，包含有效含量之如申請專利範圍第 1項至第6項任—項職的組合物，m藥可接受 的載體。 .士 ^明專利範圍第1?項所述醫藥用組合物，其中，上 述邊藥可接㈣載體為穩定劑、載體、賦形劑、稀釋劑 和其他合適物質。 〇 19.如申請專利範圍第1項至第6項、第16項至第18項任 項所述醫藥用組合物，其中，上述萃取物之含量為i 毫克至800毫克。 •如申印專利範圍第丨項至第6項、第16項至第18項任 項所述醫藥用組合物，其中，上述萃取物之最佳含量 為300毫克至5〇〇毫克。 21·使用如中請專利範圍第1項至第6項、第16項至第20 項任項所述醫藥用組合物，以降低或避免需要此治療 之哺乳類和鳥類個體的氧化壓力。 50 200940081 22. 使用如申請專利範圍第1項至第6項、第16項至第20 項任一項所述醫藥用組合物，其中，上述哺乳類為人類。 23. 使用如申請專利範圍第1項至第6項、第16項至第20 項任一項所述醫藥用組合物，其中，上述哺乳類為乳 牛、水牛、山羊、綿羊或任何其他哺乳類。 24. 使用如申請專利範圍第1項至第6項、第16項至第20 項任一項所述醫藥用組合物，其中，上述鳥類為鵝、雞、 鴨、火雞、鹤子、或任何其他鳥類。 ❹ 51200940081 * VII. Patent application scope: 1. A composition containing oil palm leaf extract, characterized in that: the extract contains catechin gallic acid, ferulic acid and phenolic acid such as gallic acid and Protocatechuic acid. 2. The composition of claim 1, wherein the oil palm leaf is derived from an oil palm plant consisting of African oil palm and American oil palm. 3. The composition of claim 1 or 2, wherein the catechin gallic acid comprises from 〇1 to 95 percent of the total weight. 4. The composition of claim 1 or 2, wherein the ferulic acid accounts for from 01 to 95 percent of the total weight. 5. The composition of claim 1 or 2, wherein the above acid is gallic acid. 6. The composition of claim 1, wherein the phenolic acid component comprises from 5% to 95% of the total weight of the total weight of the oil palm. Freshly harvested method, containing catechin gallic acid, aunt thief and _ such as gallic acid and county tea acid, including the steps: (8) dry or turn oil palm leaf with water, Lai, love, C嗣, acetic acid ethyl acetate, gas imitation, isopropanol, or a mixture of the solvents, or other polar solvent, and then heated in the range of 25 to 95 degrees Celsius / G. 5 hours to 96 hours To extract the vegetable liquid in the oil standard leaf; (b) to filter the plant liquid extracted in the step (a); (c) to contact the liquid obtained in the step (b) towel with the adsorption-precipitation substrate to 48 200940081 selective adsorption a specific component, that is, a catechin gallic acid, ferulic acid, and a phenolic acid such as gallic acid and protocatechuic acid; the adsorption matrix is a column adsorption matrix or other adsorption matrix; Alcohol, decyl alcohol, acetone, ethyl acetate, chloroform, isopropanol, or a mixture of such solvents, or other polar solvents Dissolving the components in step (C) from the adsorbent column matrix; and, 〇(e) drying the hourly mist H, vacuum oven, f-pass oven, microwave oven or freeze dryer and concentrating the above steps (d) The obtained liquid solution. 8. The method according to claim 7, wherein the method according to the above method comprises catechin gallic acid, ferulic acid and phenolic acid such as gallic acid The oil palm leaf extract of the original catechin, 9. The method of claim 7, wherein the extract is from African oil palm. Ο 1〇. The method described in claim 7 is Wherein the solvent comprises at least one of the group consisting of at least one selected from the group consisting of water, sterol, alcohol, propylene glycol, ethyl acetate, isopropanol, gas and a mixture of the solvents. The method of claim 7, wherein the separation substrate comprises a polymerization chromatography column. The method of claim 7, wherein the separation substrate comprises a synthetic polymeric resin. The method of item 7, wherein the above The resin is a polystyrene. The method of the above-mentioned drying method comprises spray drying. The oil method according to Item 7, wherein the dissolving agent 3 / a group selected from the group consisting of water, methanol, alcohol, acetone, ethyl acetate, = alcohol, H-form, or a mixture of the solvents. Ο Γ, Γ Patent (4) Items 1 to 6 - The therapeutic composition of the above-mentioned composition H/, the medium of the above composition is tea, (four), film clothing sharp, 嚼 chew, capsule, soft capsule, granules, granules, granules, granules, medicine Liquid, syrup, emulsion or suspension. A pharmaceutical composition comprising an effective amount of a composition as claimed in claims 1 to 6 of the patent application, a m-pharmaceutically acceptable carrier. The pharmaceutical composition according to the first aspect of the invention, wherein the carrier is a stabilizer, a carrier, an excipient, a diluent and other suitable substances. The pharmaceutical composition according to any one of claims 1 to 6, wherein the extract is contained in an amount of from i mg to 800 mg. The medicinal composition according to any one of the items of the present invention, wherein the extract contains an optimum amount of 300 mg to 5 mg. 21. The pharmaceutical composition according to any one of claims 1 to 6 and 16 to 20, wherein the oxidative stress of a mammal and a bird individual in need of such treatment is reduced or avoided. The medical composition according to any one of the items 1 to 6, wherein the mammal is a human. The pharmaceutical composition according to any one of claims 1 to 6, wherein the mammal is a cow, a buffalo, a goat, a sheep or any other mammal. The pharmaceutical composition according to any one of claims 1 to 6, wherein the bird is a goose, a chicken, a duck, a turkey, a crane, or Any other bird. ❹ 51
TW098105514A 2008-03-06 2009-02-20 A plant composition TW200940081A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MYPI20080538A MY157650A (en) 2008-03-06 2008-03-06 Extract from oil palm leaves comprising phenolic acids

Publications (1)

Publication Number Publication Date
TW200940081A true TW200940081A (en) 2009-10-01

Family

ID=41056226

Family Applications (1)

Application Number Title Priority Date Filing Date
TW098105514A TW200940081A (en) 2008-03-06 2009-02-20 A plant composition

Country Status (8)

Country Link
EP (1) EP2262518A4 (en)
JP (1) JP2011514347A (en)
KR (1) KR20100136978A (en)
CN (1) CN102123720B (en)
AU (1) AU2009220290A1 (en)
MY (1) MY157650A (en)
TW (1) TW200940081A (en)
WO (1) WO2009110782A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110189222A1 (en) * 2008-09-30 2011-08-04 Suhaila Mohamed Composition for wound healing
MY161839A (en) 2009-05-18 2017-05-15 Malaysian Palm Oil Board A composition for use in the prevention and treatment of cardiovascular diseases
MY185582A (en) * 2010-01-07 2021-05-24 Malaysian Palm Oil Board Anti-obesity and anti-dyslipidemic effects of oil palm phenolics in preventing atheroslerosis and cardiovascular disease
CN102504706B (en) * 2011-11-21 2013-07-10 陈永刚 Rare earth paint surface care solution
TW201741663A (en) 2011-12-29 2017-12-01 陶氏農業科學公司 Colorimetric determination of the total oil content of a plant tissue sample using alkaline saponification
US11064717B2 (en) 2013-02-20 2021-07-20 Palm Silage, Inc. Palm-based animal feed
US11071313B2 (en) 2013-02-20 2021-07-27 Palm Silage, Inc. Palm-based animal feed
MY179462A (en) * 2013-10-11 2020-11-06 Malaysian Palm Oil Board Protective effects of oil palm composition on alzheimer?s disease
CN103642850A (en) * 2013-12-10 2014-03-19 江南大学 Determination method of ferulic acid antioxidant activity in vitro
US20160278416A1 (en) * 2015-03-24 2016-09-29 Malaysian Palm Oil Board (Mpob) Methods for producing water soluble oil palm leaf powder and concentrate
CN111526735A (en) * 2017-12-27 2020-08-11 三得利控股株式会社 Composition for improving intestinal barrier function

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58144382A (en) * 1982-02-19 1983-08-27 Agency Of Ind Science & Technol Separation of tocopherol and tocotrienol
JPS62108876A (en) * 1985-11-07 1987-05-20 Mitsubishi Gas Chem Co Inc Production of vitamin e
JPS6363754A (en) * 1986-09-03 1988-03-22 Daiichi Eng Kk Method of separating carotene
JP2703241B2 (en) * 1987-12-29 1998-01-26 株式会社伊藤園 Method for producing crude catechin compound
JPH02219890A (en) * 1989-02-22 1990-09-03 Japan Tobacco Inc Anti-oxidizing agent
JP2004203848A (en) * 2002-12-20 2004-07-22 Lion Corp Composition containing vegetable extract
WO2007129136A1 (en) * 2006-05-08 2007-11-15 Achidi Valentin Agon Antimalarial properties of extracts of elaeis guineensis (oil palm) leaves
MY164863A (en) * 2007-07-11 2018-01-30 Univ Putra Malaysia Extract from palm leaves and a method for producing the same

Also Published As

Publication number Publication date
EP2262518A1 (en) 2010-12-22
JP2011514347A (en) 2011-05-06
EP2262518A4 (en) 2012-03-28
KR20100136978A (en) 2010-12-29
AU2009220290A1 (en) 2009-09-11
WO2009110782A1 (en) 2009-09-11
CN102123720B (en) 2013-11-06
CN102123720A (en) 2011-07-13
MY157650A (en) 2016-07-15

Similar Documents

Publication Publication Date Title
TW200940081A (en) A plant composition
JP6342587B2 (en) Cannabinoid purification method, composition and kit
US10864458B2 (en) Methods of purifying cannabinoids, compositions and kits thereof
JP6417630B2 (en) Sirtuin activator
US8853261B2 (en) Nutraceutical composition from Garcinia mangostana
US10155708B2 (en) Methods of purifying cannabinoids, compositions and kits thereof
WO2007119837A1 (en) Lipase inhibitor
WO2002013806A2 (en) Compositions containing hypotriglyceridemically active stilbenoids
CN111788171A (en) Use solution: method for purifying cannabinoids by liquid chromatography
JP3968405B2 (en) Antiallergic agent
WO2006137139A1 (en) Method of isolating mangosteen and drug and health food containing the same
WO2002013809A2 (en) Compositions containing hypotriglyceridemically active stilbenoids
JP2011207815A (en) Antioxidative stress agent
JP2011510912A (en) Lacanka extract-containing wound healing agent
CN102170893B (en) Compositions containing isolated tetrameric type A proanthocyanadin and methods of use and manufacture
JP2006008523A (en) Physiologically active phenolic compound and food containing the same
TW201036624A (en) Aurones as selective PDE inhibitors and their use in neurological conditions and disorders
KR101533487B1 (en) Anti-Inflammatory Composition and Anti-Urolithiasis Composition Comprising Extract from Quercus gilva Blume or Polyphenols Isolated from the Same As Active Ingredient
Ogundele et al. Comparative in vitro radical scavenging and erythrocyte membrane stabilizing activities of extracts and partitioned fractions of Artocarpus altilis stem bark and Senna alata leaf
Taslim et al. Clinical Nutrition Open Science
US10369179B2 (en) Composition of Mangifera indica
TW202313084A (en) Use of tagetes erecta extract for preparing composition for reducing blood uric acid concentration wherein the tagetes erecta extract has the feature of having non-toxicity and high anti-oxidation capability for giving consideration to both effectiveness and safety
JP2023038107A (en) Lipid synthesis inhibitor, and food and drink, processed food for inhibited lipid synthesis and expression inhibitor comprising the same
JP2002179583A (en) Antiallergic agent
PT1508334E (en) Water soluble extract from plant of solanum genus and the preparation process thereof, and pharmaceutical composition containing the water soluble extract